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T1. RADIOPHARMACOLOGY
T1-1
SYNTHESIS A POTENT FLUORINE-18 LABELLED MCHR1 ANTAGONIST 
LIGAND OF [18F]FP-PEPP
Pál Mikecz1, János Marton2, Ana Lima Oubina1, Tünde Miklovicz1, Anikó Fekete1, 
Brigitta Dürgö1, Kerstin Wolf2, Tamás Nagy1, Judit P. Szabó1, György Trencsényi1
1Department of Medical Imaging, University of Debrecen 
2ABX advanced biochemical compounds — Radeberg, Germany
INTRODUCTION: The melanin-concentrating hormone receptor1 (MCHr1) — that is found first 
in the salmon hypophysis — is responsible among others for feeding behavior of mammals [1]. 
Intracerebral injection of this hormone increases the consumed food, starvation activates the 
MCH containing neurons. Many pharmaceutical companies are putting effort to develop 
an antagonist to control obesity. On the other hand, there are attempts to activate this receptor 
in animals for increased food uptake. The development these molecules necessitate the use 
of a tracer for positron emission tomography. Our aim was to develop a new tracer, to assist 
in testing forage effects on body weight of waterfowls. The molecule chosen — 4-[(4-[18F]
fluorobenzyl)oxy]-1-[4-[2-(pyrrolidin-1-yl)ethoxy]-phenyl]pyridin-2(1H)-one — for labelling had 
already shown good brain uptake and specificity to the MCHr1 [2]. The aim of our work is to 
label this compound with F-18 isotopes.
METHODS: The synthesis of the precursor, 4-bromo-1-[4-(2-pyrrolidin-1-yl-ethoxy)- 
-phenyl]-1H-pyridin-2-one (BrPEPP), took place in 3 step starting from 4-bromo-1H-pyri-
din-2-one. The radio-synthesis started from 2–20 GBq F-18 isotopes with the fluorination of 
N,N,N-trimethyl anilinium triflate (80 oC, 5 min). The resulted [18F]Fluorobezaldehyde was re-
duced by NaBH4 on a C18 SepPak column, then was dried with He flow. The endpoint of dry-
ing was detected by measurements of the effluent gas temperature. The optimized condition 
for the labeling between the BrPEPP and the [18F]fluorobenzyl alcohol was found to 100oC, 
for 15 minutes reaction in DMF in the presence of NaH. The final product was purified on 
a semi-preparative Nucleodur Pyramide HPLC column, and formulated with ethanol and saline. 
The labeled compound was tested in healthy mice and rats, as well as on different brain slices. 
RESULTS: The overall yield of the 3 step radiochemical reaction was 20 ± 10% based on 
the isolated product of 100–3000 MBq. The radiochemical purity was > 98%, and the molar 
radioactivity was found to be 112 ± 104 GBq/μmol at the end of synthesis. In the in-vivo and 
in-vitro investigations had shown specific uptake in the hypothalamus area of the brains. Fur-
thermore, we had observed accumulation of the tracer in the adrenal gland, salivary glands, 
small intestine and in the heart.
CONCLUSION: As a result, we have a new useful tracer for investigating obesity in humans and 
to establish scientifically proven feeding strategies. The labeling took place on the aromatic 
ring, giving metabolic stability of the tracer.
Acknowledgements: This work was supported by grants FP7-PEOPLE-2012-ITN (316882 
RADIOMI project), and AGR_PIAC_13-1-2013-0008.
T1-2
PRODUCTION AND QUALITY CONTROL OF 6-[18F] FLUORO-3,4-DIHYDROXY-L- 
-PHENYLALANINE (FDOPA)
Zoltán Áncsán1, Richárd Ay1, Bálint Bojtor1, Tibor Cservenyák1, Tamás Csipak1, 
Gyöngyi Tihanyi1, Tibor Bali1, Imre Repa1, Gyöngyvér Bajtek1, Pál Mikecz2
1University of Kaposvár, PET MEDICOPUS Nonprofit LTD 
2Department of Medical Imaging, University of Debrecen
INTRODUCTION: 6-[18F]fluoro-L-DOPA is one of the oldest PET radiopharmaceuticals. Its syn-
thesis was first described in 1983. Earlier it was mainly used for neuropsychiatric diseases, 
movement disorders and malignant brain lesions. Nowadays its uses are in a wider range, for 
example it has been successfully used to diagnose neuroendocrine tumors. The widespread 
use of this tracer was inhibited, because of the only available complex electrophilic substitution 
reaction. An increasing number of methods were developed to implement high-yield nucleophilic 
synthesis in the early 2000s. Our goal was to synthetize and introduce this tracer to broaden 
the Hungarian radiopharmaceutical palette.
METHODS: The synthesis was performed with a cassette based synthesizer installed with the 
appropriate software, built and developed by TRASIS SA. The first step was the radiolabeling of 
the 6-nitroveratraldehyde precursor. This reaction was followed by reduction and halogenation. 
The forming of the whole molecule structure was achieved using a Schiff base. Then the pro-
tecting groups were removed by acid hydrolysis resulting the molecule of 6-[18F]fluoro-L-DOPA 
with high enantiomer selectivity. The material was purified by semi-preparative HPLC column, 
and it was formulated with citrate buffer. The product was sterilized by filtration on a 0.22 µm 
membrane. The quality control tests were carried out by gas and liquid chromatography and 
gamma spectrometry. In addition, pH measurements and residual phase transfer catalyst, 
Kryptofix 2.2.2 color spot tests were performed.
RESULTS: We manufactured pharmacopoeia compliant quality batches. The average decay 
corrected yield was 70%. The activity concentration of these batches were between 4.1 and 
2.8 GBq/ml. The radiochemical purity was typically < 99.5%, and the enantiomeric purity 
was found about 97%. The product was free of organic solvents that used for the production 
and pH value was between 4.1–4.4. Kryptofix 2.2.2 content was below 40 µg/ml. Each batch 
were sterile and non-pyrogenic.
CONCLUSION: On the basis of the results obtained we had applied for a marketing authori-
zation at OGYEI (National Institute of Pharmacy and Nutrition). Uniquely in the country 6-[18F]
fluoro-L-DOPA will be available for PET-CT and PET-MR studies at PET MEDICOPUS NONPROFIT 
Ltd. in the second half of 2017. This would broaden the slim palette of radiopharmaceuticals for 
PET examinations in Hungary.
T1-3
SIGNIFICANCE OF PH CONTROL IN DETERMINATION OF RADIOCHEMICAL 
PURITY OF F-18 LABELED TRACERS USING LIQUID CHROMATOGRAPHY
Csaba Hámori, Cintia Anna Balogh, István Jószai*
Department of Nuclear Medicine, Clinical Center, University of Debrecen
INTRODUCTION: Synthesis of [18F]FDG as well as [18F]FET is based on participation of [18F]
fluoride ions in SN2 nucleophile reaction. However, liquid chromatographic methods may used 
in quality control of these radiopharmaceuticals are not useful for detection of [18F]fluoride ions. 
Determination of free radioactive fluoride could be achieved using additional TLC method. The 
aim of this work was to examine the effect of pH of the eluent for elution of [18F]fluoride ions to 
determine the total radiochemical purity by single HPLC method. 
METHODS: Composition of the applied HPLC system was as follows: Jasco autosampler, 
degasser, low pressure gradient valve, pump, radioactivity detector. Waters I-Class system 
was applied for UPLC measurements. The used analytical columns were Acquity UPLC, 
BEH Amide 1.7 μm, 3.0 × 100 mm (Waters), LiChroCART NH2, 5 μm, 250 × 4 mm, (Merck), 
LiChroCART RP18, 5 μm, 250 × 4 mm, (Merck). Reference materials were prepared either on 
synthesis modules or manually [1].
RESULTS: In quality control of [18F]FDG the separation of active ingredient from the intermedier 
[18F]TAG is possible on LiChroCART NH2 column with MeCN/H2O (95/5 V/V%). On the other 
hand, the elution of [18F]fluoride ions is only possible using buffer solution with pH7. The 
following gradient method is could be applied for determination of total radiochemical purity 
of [18F]FDG. The elution started with acetonitrile/phosphate buffer (pH7; 5 mM) in the ratio of 
85/15 V/V%. To elute [18F]fluoride eluent composition is to be changed to acetonitrile/phos-
phate buffer (pH7; 5 mM) in the ratio of 5/95 V/V%. Gradient profile: 0 min 100% A — 0% 
B, 2 min 100% A — 0% B, 3 min 0% A — 100% B, 7 min 0% A - 100% B. At 2 mL/min flow rate 
the measurement time was 7 minutes. Retention times: 1.303 min [18F]TAG, 2.485 min [18F]
FDG, [18F]fluoride ion 5.143 min. The resolution between [18F]TAG and [18F]FDG was 4.2 and 
between [18F]FDG and [18F]fluoride was 10.2. The developed method was successfully trans-
ferred to UPLC system. In case of UPLC procedure Amide column was applied. The elution 
started with acetonitrile/ammonium acetate buffer (pH5; 50 mM) in the ratio of 90/10 V/V%. 
To elute [18F]fluoride eluent composition was changed to ammonium acetate buffer (pH10; 
50 mM) in the ratio of 10/90 V/V%. Gradient profile: 0 min 100% A — 0% B 1.2 mL/min, 1.20 min 
100% A — 0% B 1.2 mL/min, 1.25 min 0% A — 100% B 0.6 mL/min, 1,50 min 0% A — 100% 
B 0.4 mL/min, 5.00 min 0% A — 100% B 0.4 mL/min. Retention times: [18F]TAG 0.393 min, 
a [18F]FDG 1.024 min, a [18F]fluoride 3.045 min. The resolution between [18F]TAG and [18F]FDG 
was 2.8 and between [18F]FDG and [18F]fluoride was 6.9. In case of [18F]FET we implemented 
the elution of [18F]fluoride ions on LiChroCART RP18 column with pH7 phosphate buffer. The 
recovery of [18F]fluoride ions was higher than 95%.
CONCLUSION: This work gives recommendations on determination of total radiochemical 
purity of [18F]FDG as well as [18F]FET using liquid chromatographic technique. Single analyti-
cal method could simplify the quality control of tracers as well as to increase the productivity 
of Q.C. management.
1. Hamacher K, Coenen H, Stöcklin G. J Nucl Med. 1986; 27: 235–238.
T1-4
SYNTHESIS OF F-18 LABELED N-SUCCINIMIDYL 4-[18F]
TRIFLUOROMETHYLBENZOATE
Péter Szücs1, 2, Pál Mikecz1
1Department of Medical Imaging, University of Debrecen 
2University of Debrecen
INTRODUCTION: The F-18 isotope is one of the best PET isotope with its 109.7 min half-time, 
low positron energy and high positron emission rate. Trifluoromethyl group is widely used in 
drugs as bioisostere group for stabilizing a compound or protecting a reactive methyl group. 
The aim of our project was to work out a synthesis method of a benzoic acid derivate with 
trifluoromethyl and active ester group. This derivate can be good for effective labeling com-
pounds with amino group, such as peptides and nanoparticles.
METHODS: The synthesis of the labeling molecule was consisted multiple steps. In the first 
step ethyl 4-[18F]trifluoromethyl benzoate was made from ethyl 4-iodobenzoate using CuI and 
methyl chlorodifluoroacetate at 150°C for 20 min with a cross coupling reaction. The derivate 
was separated on a Macherey-Nagel Nucleodur C18 Pyramid (250 × 10 mm, 10 μm) semi-prep 
HPLC column. The product was hydrolyzed with tetra-methyl ammonium hydroxide at 90 °C for 
5 min. The reaction mixture was passed through a C18 Sep-Pak cartridge and the benzoic acid 
derivate was eluted. TSTU solution was added and the mixture was heated at 90 °C for 5 min to 
produce N-succinimidyl 4-[18F]trifluoromethylbenzoate. The quality control was performed on 
Macherey-Nagel Nucleodur C18 Pyramid (250 × 10 mm, 10 μm) HPLC column with isocratic 
70:30 = MeCN:H2O (0.1% TFA) eluent.
RESULTS: The radiochemical yield of ethyl 4-[18F]trifluoromethyl benzoate was 58 ± 14% (n = 8) 
with the manual method, but the method was reproduced with automated synthesis, too. The 
separation of the production on the semi-prep HPLC column resulted pure intermediate prod-
uct. The hydrolysis of the ethyl 4-[18F]trifluorometyhl benzoate to 4-[18F]trifluorometyhlbenzoic 
acid had 100% conversion rate. The cleaning process of the benzoic acid derivate was found 
effective on the C18 Sep-Pak cartridge. The radiochemical yield of the N-succinimidyl 4-[18F]
trifluoromethylbenzoate was 88 ± 13% (n = 5).
CONCLUSION: The synthesis of the N-succinimidyl 4-[18F]trifluoromethyl benzoate with [18F]
trifluoromethyl group was successful. The active ester group of the molecule makes possible 
its use for labeling peptides and amino group containing nanoparticles. We successfully 
worked out a fast and simple analytical process for the separation of the compounds. The 
automatization of the synthesis is in progress.
Nuclear Medicine Review 2017, Vol. 20, No. 2
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T1-5
DEVELOPMENT OF A STOPPED FLOW CAPILLARY SYSTEM  
FOR RADIOLABELING
Dezsö Szikra1, 2, Gábor Nagy2, György Trencsényi1, 2, Ildikó Garai1, 2
1Medical Imaging Clinic, University of Debrecen 
2Scanomed Ltd., Debrecen
INTRODUCTION: The systematic variation of reaction conditions is required to determine 
the optimal labeling conditions in order to maximize the yield, the radiochemical purity and 
the specific activity of the labelled product. This procedure is often time consuming and 
hampered by the high deviation of experimental results, associated to non-carrier added 
isotopes. A stopped flow capillary system was developed on the basis of our previous experi-
ence with a continous flow system. It enables the fast optimization of labeling conditions of 
various chelators with 68Ga and 44Sc. The system was designed to handle small reagent 
volumes for scouting experimets and to be able to scaled up to larger volumes for production.
METHODS: The capillary system consists of three electronically actuated HPLC valves (Rheo-
dyne Titan MHP) interconnected with teflon capillaries (0.25 mm i.d.) and controlled by an Ar-
duino Mega card. The liquid is moved by the aid of a double syringe pump. The reagents are 
coinjected into a heated PEEK loop (0.15 mm, 25 ml) and — after the predetermined reaction 
time — injected onto a HPLC column for analysis.
RESULTS: The dependence of RCY on pH and chelator concentration was determined for 
various chelators (DOTA, NOTA, NOPO) labeled with 68Ga and 44Sc. DOTA and NOTA gave 
similarly high yields (80–85%) at pH4. 95oC, 5 min, but the NOP O chelator, which is tailored to 
gallium gave low RCY (20%) with 44Sc. Besides the free chelators, maleimide chelator deriva-
tives (DOTA-, DOTAGA-, NOTA-, NODAGA-maleimide) were also tested in order to simulate 
the labeling of peptide conjugated chelators. In the case of gallium labeling, the difference 
between the chelators was small among the applied experimental conditions. Scandium label-
ing experiments showed more significant differences, and DOTAGA- and NODAGA-maleimide 
were found to be better than the DOTA and the NOTA derivatives. This can be explained by 
the higher stability of scandium complexes with high coordination numbers (8 for DOTAGA 
and NODAGA vs. 7 for DOTA and NOTA). 
CONCLUSION: The developed system is more flexible than its previous version, which ap-
plied continuous flow of water to move the reagents across the system. The stopped flow 
operation enables the simple change of residence time and decreases activity loss caused by 
diffusion. 70% of the reaction mixture is injected onto the HPLC column for separation, which 
was only 50% for the previous system. The intra-day reproducibility of the radiochemical yield 
was high (1% RSD, n = 5).
T1-6
LOCAL Preparation and analysis of 68-GA-DOTA-TOC injection for clinical 
application
Gergely Jánoki1, Csaba Révész3, Lajos Balogh2, Ágota Esek Smelkóné3,  
Gyözö Jánoki1
1Medi-Radiopharma Ltd., Érd 
2OSSKI, Budapest 
3Radiopharmacy Laboratory Ltd., Budaörs
INTRODUCTION: Preparation of radiopharmaceuticals for diagnostic and therapeutic applica-
tion at the user’s location provides new opportunities for the nuclear medicine laboratories.
We would like to demonstrate the requirements of the European Pharmacopeia (Pharm.
Eur.8.7.,04/2016:54900) with a practical example in order to facilitate the initial activities of 
local preparation of radiopharmaceuticals.
METHODS: During the labelling reaction the used materials were very pure and heavy 
metals-free were the followings: DOTA-TOC GMP grade; Sodium acetate, highly purified water 
and 96% ethanol (Merck). 50 μg DOTA-TOC conjugate were dissolved in 200 μl 0.25M Sodium 
acetate buffer (pH 5.0) then we mixed it with the 1mL volume, 100–150MBq activities fraction-
ated eluted 68-Ga chloride 0.05N HCl solution in the labelling vial. After mixing the reaction 
solution was heated at 90°C for 10 minutes, then after chilling down to room temperature it 
was filtered with 0.22 micrometer membrane filter. The final volume of the injection was set to 
5 mL with sterile PBS solution.
After this process the analytical examinations were performed. Radiochemical purity was de-
termined by radio-HPLC, ITLC and paper chromatography methods.
RESULTS: The radiochemical purity results of the three consecutive labelling reaction were 
the followings: 1) 99.1%; 2) 98.5%; 3) 98.3%.
The quantities of Impurity A and B together were in all cases around 1%. The labelled solu-
tion pH value was between 4.5–5.0. The solution for injection was clear, transparent; ethanol 
content was below 10%. Sterility and bacterial endotoxins tests were performed retrospectively 
and the results were conforming as well (sterile and less than 175 IU/mL). Organ distribution 
test performed on rats showed quick excretion through kidney (more than 70% I.D.) and low 
blood activity (less than 1.2% I.D.). We would like to continue with further examinations re-
quired by the legislations, so as the impact analysis of the heavy metal impurities (Fe, Zn) of 
the generator‘s mother element (Ge). Likewise, the integrity test of the membrane filter used 
for the sterile filtration is performed each time and the aseptic conditions of the preparation 
are check by Media-Fill.
CONCLUSION: The local ex tempore prepared 68-Ga-DOTA-TOC injections for PET/CT dia-
gnosis of neuroendocrine tumors conforms to the prescriptions of the Pharmacopeia based 
on the qualifying tests we performed.
After performing and validating the additional tests with the preparation of its confirming 
documentation, this preparation method can support the application for the license of local 
preparation of radiopharmaceuticals.
The research was realized with the support of GINOP-2.1.1-15-2015-00592 project.
T2. IMAGING TECHNIQUE, IMAGE PROCESSING
T2-1
FEASIBILITY STUDY OF A HUMAN TISSUE EQUIVALENT PHANTOM
Melinda Szoliková1, Attila Forgács1, Gábor Nagy1, Mihály Zentai2, Ildikó Garai1
1ScanoMed Ltd., Debrecen 
2Mediso Ltd., Budapest
INTRODUCTION: In the recent years the emission and transmission imaging techniques com-
bining PET/CT and SPECT/CT hybrid devices spread rapidly. Their advantage in addition to the 
integration of anatomical and functional information, is the correction of radiation attenuation 
and scatter within the body of the patient. This could be performed using CT segmentation, and 
therefore, the activity-concentration of the distributed radiopharmaceutical can be measured 
accurately. The aim of our study was to create a phantom which can represent the entire range 
of attenuation coefficients specific for the human tissues. This method would be suitable to 
assure the quality of reconstructions using CT-based attenuation correction (PET, SPECT).
METHODS: To mimic the lung equivalent compartment, a given volume was field with 
Styrofoam® beads surrounded by isotope in water solution. The fat tissue was imitated by 
an oil-isotope mixture, and the muscle by a ballistic gel-isotope mixture. Furthermore, the bone 
section was a hollow shin bone of a cattle. It was possible to generate homogenous activity-dis-
tributions using the material combinations mentioned above. In case of the oil mixture, as the 
applied F18-FDG and TcO4 are water-based, they were firstly evaporized at high temperature, 
then they were diluted in isopropyl alcohol. Finally, PET/CT and SPECT/CT measurements and 
reconstructions of the compiled phantom were performed.
RESULTS: We measured (–650)–(–800) HU values in the lung equivalent component, (+50)–
(+100) HU values in the ballistic gel, (+400)–(+800) HU values in the bone, and (–50)–(–100) 
HU values in the oil. The phantom covered the whole Hounsfield Unit spectrum of the tissues of 
the human body, measured from the lung till the bone. In addition, the measured standard 
uptake values and activity-concentrations fell within 10% margin of error compared to the 
values estimated from the known of activity, mass and volume of each compartments.
CONCLUSION: In this study, we proved successfully the introduction of ballistic gel and oil 
as a possible candidate of new phantom materials. Moreover, this human equivalent phan-
tom (as an easy to create tool) can be an alternative way to support the quality assurance 
of hybrid devices.
T2-2
IMAGE RECONSTRUCTION OPTIMISATION FOR BRAIN PET/CT 
Attila Oszlánszki, Attila Forgács, Zsolt Hascsi, Bernadett Dobainé Szücs,  
Ildikó Garai
Scanomed Ltd., Debrecen
INTRODUCTION: Positron Emission Tomography (PET) became an essential non-invasive 
diagnostic imaging technique in the last two decades. Moreover, it plays an increasingly im-
portant role in terms of functional brain mapping. The image processing and writing of medical 
reports after a PET/CT examination needs continuous optimisation to reach more accurate 
results. Our aim in this study was the optimisation of reconstructions (including post-filtering) 
for 18F-FDG and 11C-MET brain PET images.
METHODS: Dynamic PET acquisition of the 3D Hoffmann phantom were performed on the 
MEDISO Anyscan PC and PHILIPS Gemini 64 systems. The applied total activities were primar-
ily estimated based on the literature. The measurement of the phantom corresponded to the 
routine patinet examination protocol. We made reconstructions using the available options on 
the MEDISO Anyscan PC acquisition software: varying the number of iterations (from 4 to 
16), the voxel-size (4 mm, 3 mm, 2 mm, 1 mm), and appling different post-filters (3D Gauss, 
3D Bilateral etc.). During the comparison of the reconstructions, volumes of interests (VOIs) 
were defined based on segmentation of the CT images. Standard deviation, mean- and 
variability-coefficients were calculated from the applied VOIs. Furthermore, optimisation of 
reconstructions was made on real patient datasets, but only in the range that was restricted by 
the phantom. The patient records were compared based on visual assessment of experienced 
nuclear medicine physicians.
RESULTS: After more than 100 processed image sequences, our results showed that the 
dedicated brain images signify higher total counts than the frames of whole body aquisitions. 
This permits the use of higher number of iterations and the 1–2 mm voxel-size. In case of 
11C-Methionine, we received the most optimal recontruction from the raw data using high 
number of iterations (10–14) and properly parameterized bilateral filter (3 kernel, 1 sigma). 
However, in case of the 18F-FDG brain examination, even a higher number of iterations led to 
the optimal result, while using similar filtering. 
CONCLUSION: A given type of PET examination requires not only a specified aquisition, but 
also a dedicated reconstruction with optimized parameters to the specific radiopharmaceutical. 
The findings of this study made it possible to improve the quality of medical reports at our site.
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T3-3
EVALUATION OF HEPATIC FDG UPTAKE DURING LYMPHOMA RESPONSE 
ASSESSMENT PET/CT
Zoltán Tóth1, 8, Gábor Lukács2, 3, 7, Péter Rajnics4, Miklós Emri1, 6, Zsolt Cselik2, 5, 
Lívia Zilahi1, Zsuzsanna Gábor7, Miklós Egyed4, Imre Repa2, Árpád Kovács2, 7
1PET Medicopus Nonprofit Ltd., Health Center, University of Kaposvár; 2Department of 
Diagnostic Imaging and Radiation Oncology, Health Center, University of Kaposvár; 
3Department of Oncology, Somogy County Móricz Kaposi Teaching Hospital; 4Department 
of Haematology, Somogy County Móricz Kaposi Teaching Hospital; 5Radiation Oncology, 
Regional Oncology Center Veszprém; 6Department of Medical Imaging, University of 
Debrecen; 7Medical Laboratorial Diagnostic Imaging Analysis BSC, Department of Medical 
Imaging Kaposvár Campus, University of Pécs Faculty of Health Sciences; 8Doctoral School 
of Health Sciences, University of Pécs
INTRODUCTION: For the FDG PET/CT based visual therapy response assessment of lym-
phoma liver became the most important reference organ recently. The aim of the current project 
was to assess the stability of hepatic tracer uptake during chemotherapy treatments and to 
evaluate the potential change characteristics. 
METHODS: Retrospective analysis was performed using the imaging data of 55 lymphoma 
patients (19 Hodgkin’s disease, 36 Non-Hodgkin’s lymphoma). All subjects underwent PET/CT 
for initial staging, after 2–4 cycles of chemotherapy for early response assessment and after 
completion of 6–8 cycles of therapy for restaging purposes. Hodgkin’s disease patients re-
ceived ABVD therapy, for Non-Hodgkin’s lymphoma patients CHOP-based therapeutic regimen 
was administered. Mean and maximal hepatic standardized tracer uptake values (SUV) — using 
body weight, lead body mass and body surface area related normalization — were calculated 
with PERCIST liver reference ROI auto-segmentation tool of Syngo.via image processing ap-
plication. The average hepatic Hounsfield values (HU) were also calculated using the same VOI 
on the low-dose CT images. For the evaluation of treatment associated hepatic SUV and HU 
changes one and two way Tukey’s post hoc test was used after analysis of variance. One-way 
model was used when the type of lymphoma was ignored, and two-way method was assessed 
when the changes were examined within the two lymphoma subgroups.
RESULTS: None of the performed tests could reveal statistically significant alteration for any of 
the investigated SUVmax and SUVmean or average HU parameters. Further analysis was per-
formed after creating 3 subgroups from the subjects according to the hepatic HU value changes. 
In the first group the reduction of hepatic average HU was larger than 10% (17 people), for the 
2. group the HU value alteration was less than 10% (29 people). The 3. group contained the 
subjects with more than 10% increase in HU values (9 people). For the 1. group the reduction 
of HU values were found to be significantly lower during and after the treatment with p < 0.0001 
than the value before the treatment. However, changes in SUV values were not found to be 
significant within this subgroup, as patients with increased and decreased SUV values were 
also occurred. The other two (2–3) subgroups had no statistically significant HU change, due 
to small changes (2. subgroup), and as a consequence of low subject number (3. subgroup).
CONCLUSION: The survey, containing the data of our own patient population reassuringly 
confirms the stability of liver activity during lymphoma response assessment FDG PET/CT 
examinations, we were unable to demonstrate any significant alteration restricting the further 
use of liver as a visual reference organ. 
T3-2
PREDICTIVE ROLE OF FDG PET/CT IN HEAD AND NECK CANCER TREATED 
WITH RADIOTHERAPY — PRELIMINARY RESULTS 
Zoltán Tóth1, 7, Gábor Lukács2, 3, 7, András Kedves6, Miklós Emri1, 5, Zsolt Cselik2, 4, 
Gábor Toller2, Éva Ferenczy1, Ferenc Lakosi2, Janaki Hadjiev2, Imre Repa2,  
Árpád Kovács2, 7
1PET Medicopus Nonprofit Ltd., Health Center, University of Kaposvár 
2Department of Diangostic Imaging and Radiation Oncology, Health Center, University of 
Kaposvár 
3Oncology Department, Somogy County Mócicz Kaposi Teaching Hospital  
4Radiotherapy, Oncology Center Veszprém  
5Department of Medical Imaging, University of Debrecen  
6Medical Laboratorial Diagnostic Imaging Analysis BSC, Department of Medical Imaging 
Kaposvár Campus, University of Pécs Faculty of Health Sciences 
7Doctoral School of Health Sciences, University of Pécs
INTRODUCTION: FDG PET/CT provides crucial information for the proper staging assessment 
and radiotherapy planning (RTP) of head and neck cancer patients. Our aim was to search 
for therapeutic outcome predicting parameters in the pre-treatment functional imaging data.
METHODS: Retrospective evaluation was performed using PET/CT image datasets of 21 head 
and neck cancer patients. PET/CT was acquired before the therapy, used for RTP and repeated 
3–6 months after the completion of therapy for response evaluation. From the pre-treatment 
image datasets we assessed the SUVmax, SUVmean, Metabolic Tumor Volume (MTV) and 
Total Lesion Glycolysis (TLG) parameters of the primary tumor. According to the results of the 
therapeutic response evaluation PET/CT and the clinical follow up two patient subgroups were 
created in relation to the presence or absence of viable primary tumor tissue. Subgroup related 
metabolic parameter evaluation was performed (Wilcoxon test).
RESULTS: After radiotherapy in 10/21 cases viable residual tumor tissue was detected 
on the restaging PET/CT image dataset and 11/21 subjects reached complete remission. 
For the therapeutic success prediction assessment we were unable to find any correlation 
with pre-treatment SUVmax and SUVmean values (p = 0.55 ill. p = 0.32). MTV and TLG 
parameters however provided statistically significant differences between the two patient 
subgroups [MTV (p = 0.008), LTG (p = 0.020)], as a summary MTV proved to be the most 
useful parameter for therapeutic response prediction. 
CONCLUSION: Simple metabolic data provided by FDG PET/CT were unable to predict 
therapeutic response, while according to our preliminary results complex volume information 
containing parameters proved to be more useful for this purpose, thus their inclusion to risk 
stratification may have of additional value. Survey is planned to be followed with more subject 
and parameter inclusions. 
T3. ONCOLOGY — PET
T3-1
INCIDENTAL LESIONS IN FDG-PET/CT SCANS
Gábor Sipka1, Zsuzsanna Besenyi1, Zsolt Lengyel2, László Pávics1
1Department of Nuclear Medicine, University of Szeged 
2Pozitron Diagnosztika Ltd., Budapest
INTRODUCTION: The modern oncological diagnostics are unimaginable without FDG-PET/CT. 
During the metabolic information gaining process we often discover different, incidental lesions, 
which aren’t connected to the primary tumours. Our goal in the study was to retrospectively 
specify the origins of these freshly discovered, independent FDG-avid lesions in „routine” 
FDG PET/CT scans. 
METHODS: We revised 326 FDG-PET/CT exams’ results, which are asked by the most different 
oncologic indications, from 2006 February to 2012 January (229 men, 97 women; average age: 
57.4 year). According to the written results we classified the PET findings and separate those 
FDG-avid lesions, which aren’t connected to the primary malignancies. Under the 2 years follow 
up we could define the incidentalomas exact locations, states and malignancies. The correct 
histological identifications and the long follow up time were essential in our study, because 
we could accurately isolate and evaluate the benign and malignant diseases from each other. 
RESULTS: 119 abnormal, unexpected, focal lesions were confirmed in 112 patients out of 
326. All in all 18 (5.5%) newly detected, separate, primary malignancies were certified, while 
19 (5.8%) metastases and 82 (25.1%) benign diseases have been described as well. Location-
ally, greater part of the incidental lesions were found in the gastrointestinal system and in the 
head and neck region (35–35), while the respiratory- and urogenital system, the skin and other 
locations contained the remaining part (30%). In point of the digestive tract the most focal, 
FDG-avid findings were in the colon (24/42), but none of them was malignant, on the other 
hand the findings in the stomach and pancreas were decisively more aggressive. The head 
and neck lesions were often proved to the primary disease’s metastasis (10/13). Surprisingly 
no histological confirmed malignant lesion was detected in the thyroid gland. The other find-
ings in the suprarenal gland and in the lung were equally metastases and newly discovered, 
primary malignant tumours.
CONCLUSION: In summary, we can detect unexpected, incidental lesions in the third of the 
FDG-PET/CT scans. Most of them are benign, although significant part of these FDG-avid 
lesions, approximately and another third part of the all suspicious findings are progressive, 
malignant, pathological diseases, which raise the patients’ mortality. The most false positive 
signs can be detect in the gastrointestinal system.
T2-3
The Impact of the Q.Clear Reconstruction Algorithm on the Quantitative 
Evaluation of Hepatic Metastases Shown on 18F-FDG-PET/CT Studies  
— Preliminary Results
Sándor Czibor, Zsolt Varga, Attila Fekésházy, Edit Takács, Linda Jorgov, Béla Kári, 
Boglárka Magyar, Judit Török, Gabriella Dabasi, Tamás Györke
Semmelweis University, Nuclear Medicine Centre, Budapest
INTRODUCTION: PET/CT scans are routinely reconstructed by iterative algorithms, where 
a well-known limitation is the worsening of the signal-to-noise ratio when increasing the number 
of iterations. A novel Bayesian penalized likelihood reconstruction algorithm (Q.Clear) has al-
lowed more iterations without simultaneously significantly increasing noise levels that results in 
a better signal-background ratio. The aim of our study was to compare this algorithm with the 
conventional OSEM reconstruction by investigating 18F-FDG-PET/CT studies.
METHODS: We investigated the 18F-FDG-PET/CT studies of 9 patients (6 women, 3 men) 
and a total of 24 FDG-avid hepatic metastases were included in our sample. The raw data 
of each patient were reconstructed by both the OSEM and the Q.Clear algorithm. A spheric 
VOI of 3 cm diameter was placed in the normal hepatic tissue as reference and a spheric VOI 
was manually adjusted to the metastases, both in an identic location in the two differently 
reconstructed studies of each patient. The size of the lesions were calculated by the largest 
axial diamater measured on the CT scans. Standardized uptake values (SUV) based on body 
weight were calculated, including SUVmax and SUVmean. Noise was defined as the standard 
deviation of the normal liver parenchyma SUV. Signal-to-noise ratio was given as SUVmean 
in the normal liver parenchyma divided by the noise. Signal-to-background ratio was defined 
by SUVmax in a lesion divided by the SUVmean in the normal liver parenchyma. Two-tailed 
paired sample t-tests were calculated to compare the datasets.
RESULTS: The average size of the lesions was 18 ± 8.85 mm (range: 10–53 mm). The 
Q.Clear algorithm resulted in significantly higher SUVmax and SUVmean values in the le-
sions (p < 0.001): ∆SUVmax 2.12 ± 1.75; ∆SUVmean 0.50 ± 0.48. The signal-to-background 
ratio was significantly better with Q.Clear (3.33 ± 2.45 vs. 2.87 ± 2.26; p < 0.001) while 
signal-to-noise and SUVmean-to-noise ratios were not significantly different. The latter can be 
explained with the (nonsignificantly) higher levels of noise by using Q.Clear.
CONCLUSION: Our study showed that the Q.Clear reconstruction algorithm resulted in better 
signal-to-background ratios without the decrease of the signal-to-noise ratio in FDG-avid hepatic 
metastases which leads to better recognition and characterization of the lesions.
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T4-2
TREATING PAINFUL BONE METASTASES OF PROSTATE TUMORS  
WITH A-RADIATING ISOTOPES
Margit Sarkadi, Katalin Zámbó
Department of Nuclear Medicine, University of Pécs
INTRODUCTION: 223-radium-dichloride (Xofigo) is an a-particle emitting radionuclide with 
an advantageous toxicity profile, which is recommended for treating bone metastases causing 
symptoms in castration-resistant prostate cancer patients when no visceral metastases are 
present. It can be used following Docetaxel therapy for achieving extended survival time in 
patients experiencing progression of the disease. The study was undertaken to find out about 
the effectiveness of the treatment.
PATIENTS AND METHODS: In our Department 33 interventions in 7 patients were performed 
from July 2015 through December, 2016. The mean age of the patients was 70 years (range 
61–78 years). Four patient received treatment on 6 occasions each, one patient received treat-
ment on 5 occasions and another one patient received Xofigo treatment on 3 occasions (the 
third one was performed in another department.)
RESULTS: An average of 4.7 treatments were performed in our patients, i.e. treatment 
was provided in 78 percent of the cases. Significant results were found in terms of the treat-
ments performed. Patients receiving treatment on 6 or 5 occasions reported significant decrease 
of the bone pain, in 2 patients the pain even stopped. In another 2 patients the 10 value on 
the pain scale dropped to 0 and in 3 patients it dropped to 3, which means that the change 
can be called significant. Remarkable improvement in our patients’ quality of life could also be 
observed. The evaluation of the treatment received by a low number of patients revealed find-
ings similar to those of the ALSYMPCA study and the international EAP analyses, i.e. full survival 
time (OS) was longer and the bone pain intensity significantly decreased in patients having 
received 5–6 treatments as opposed to those who could receive the injection only 1–4 times. 
The majority (68%) of patients having received 223 radium dichloride treatment also got 5–6 
injections. Median OS was 16 months in the whole cohort.
CONCLUSION: In addition to prolonged survival time the preservation of the quality of life 
is also important. In early-stage bone metastases Xofigo improves both the survival time 
(OS) and quality of life. The maximum advantages of 223 radium dichloride treatment can 
be enjoyed by patients having received treatment on 5–6 occasions. We should do our best 
for our patients to access all possible therapies, which makes effective cooperation with the 
other specialties indispensable.
T4. THERAPY, RADIATION PROTECTION
T4-1
30 YEARS OF RSO IN HUNGARY 
Margit Szentesi, Zoltán Nagy
Polyclinic of the Hospitaller Brothers of St. John in God, Budapest (BIK)
The first publication about Radiosynoviorthesis (RSO) appeared in 1952 by the author Fellinger. 
In Hungary the first RSO was performed in 1985 in the National Institute of Rheumatology 
and Physiotherapy. From 2000 the RSO is performed at BIK. The treatment was introduced 
in Kecskemét and in the Uzsoki Hospital in 2000. and later in Szeged and Debrecen as well. 
THE ACHIEVED RESULTS IN THE SUBJECT:
We were the first to introduce radiosynoviorthesis (RSO) in our country.
We compiled a points system for the evaluation of RSO.
We proved the efficiency of the method by following up many patients (8000) for a long 
period of time.
Using multifactorial regression analysis we proved that efficiency of RSO is influenced primarily 
by the local x-ray stage of the joint and the diagnosis of the main disease.
We proved that the best results can be expected in Steinbrocker stage I.–II., local stage I.–II. of RA.
We proved that among patients with SPA the ratio of excellents and goods together is only 
46.8% but 70.6% of the patients don’t need further punction.
We proved that the treatment is also useful in inflamed patients with OA.
We proved that in case of synovitis of traumatic origin when the synovitis persists after the 
proper surgical treatment of the change maintaining only the synovitis, the usage of this method 
should be weighed.
We proved that in patients who underwent orthopedic surgical operation earlier the result of 
this is as good as in those without previous operation.
We proved that the efficiency of RSO is not influenced by the duration of synovitis, the number 
of punctions preceding RSO, the number of intraarticular steroid injections before RSO, the 
gender and the age of the patient.
For objective following up of RSO we elaborated arthroscopic and histologic method.
AFTER 2000: We elaborated and proved by animal experiments, toxicologic, clinical, ultrasound 
and isotope examinations that Holmium-166 phytate is a suitable isotope for RSO.
With draining examinations, we proved that radiation exposure by 166-Holmium-phytate 
is minimal.
With chromosome examinations, we proved that 166-Ho-IHPP does not cause chromosome 
damage.
We have the 166-Ho-IHPP registered.
The HBCS made for the usage of 166-Ho-IHPP has come into force.
We proved that RSO is also effective for the treatment of chronic synovitis beside biologic 
therapy.
We proved that the efficiency of RSO can be measured by the following: dynamic knee joint 
scintigraphy; following up with ultrasound, arthroscopy, and histology; our objective scoring 
system; and the necessity of punctions after RSO.
T3-5
EVALUATION OF 11C-CHOLINE PET/CT FOR RESTAGING OF PROSTATE 
CANCER
Hascsi Zsolt, Forgács Attila, Káplár Anna, Garai Ildikó
ScanoMed Ltd., Debrecen
INTRODUCTION: 11C-Choline PET/CT is one of the most sensitive diagnostic tools for detect-
ing locally recurrent and metastatic prostate cancer. 11C-Choline PET/CT has been available in 
human care since 2014 in our country.
Our aim was to determine the diagnostic role of 11C-Choline PET/CT in patients with biochemi-
cally recurrent prostate cancer who initially underwent radical therapy.
METHODS: This retrospective study enrolled 100 prostate cancer patients initially treated 
with radical prostatectomy (followed by radiation and/or hormone therapy) or radiotherapy 
(with or without hormone therapy). The median age of the patients was 66.3 years (49 to 87 
years). Patients with unknown PSA level and those who received only hormone therapy were 
excluded. The average pretest PSA level was 6.91 ± 10.26 ng/ml (median: 3.27 ng/ml, 0,008 
to 50 ng/ml) and the median Gleason score was 7 (4–10). 
The PET/CT acquisition (6 to 8 frames each for 120 sec) started 5 minutes after the iv. injection 
of 700–850 MBq 11C-Choline. For attenuation correction and anatomical localization low dose 
CT was done (120 keV, 150 mAs). 
Statistical analyses were performed both, on a patient and lesion basis to assess the relation-
ship between PET positive findings and PSA level, type of initial treatment and tumor grade. 
RESULTS: Seventy-two patients underwent radical prostatectomy, while 28 patients were 
initially treated with radiation and 50% of the overall patient population received hormone 
therapy as well. We found a significantly higher PSA level in the PET positive patient group, the 
median level of the PSA was 5.25 ng/ml and 0.95 ng/ml in the PET positive and PET negative 
patient subgroup, respectively (Mann-Whitney U test, p = 0.000). Significantly higher Gleason 
score was characteristic for PET positive patients (Mann-Whitney U test, p = 0.04). The lesion 
based analysis showed significant difference in PSA level (Kruskall-Wallis test, p = 0.000).
CONCLUSION: 11C-Choline PET/CT is a sensitive study in the setting of locally recurrent or 
metastatic prostate cancer. The strong correlation of this method with the PSA test results is help-
ful in determining the timing of imaging.
T3-4
CORRELATION BETWEEN METABOLIC ACTIVITY AND 
CLINICOPATHOLOGICAL FACTORS IN BREAST CANCER
Bence Farkas1, 2, Attila Forgács2, Ildikó Garai1, 2
1Division of Nuclear Medicine, Department of Medical Imaging, University of Debrecen 
2ScanoMed Ltd., Debrecen, 
INTRODUCTION: Breast cancer is the most common malignancy among women. Therefore, 
correlations between the clinicopathological prognostic factors of breast cancer and numer-
ous parameters obtained by 18F-FDG PET/CT (e.g. SUVmax) are well studied issues. However, 
there are still discrepancies in the literature.
Our aim is to examine correlations between SUVmax values and the clinical status of the 
patients as well as immunohistochemical characteristics of primary breast tumors.
METHODS: We assessed the baseline 18F-FDG PET/CT scans and histological reports of 96 
breast cancer patients. Only patients with a primary tumor diameter larger than 2 cm were 
included in this study to minimize bias caused by partial volume effect. Mann-Whitney U test 
and Spearman’s correlation were performed to find associations between SUVmax and the 
following clinicopathological prognostic factors: size of the primary tumor, histological type, 
grade, estrogen, progesterone and HER2 receptor status, MIB-1 proliferation index, and the 
presence of local lymphatic and distant metastases.
RESULTS: We found connections between SUVmax values of the primary tumor and the 
following parameters: estrogen (p = 0.003), progesterone (p ≤ 0.001) and overall hormone 
receptor status (p = 0.001), HER2 receptor status (P = 0.002), grade (p ≤ 0.001), triple 
negative phenotype (p = 0.013), and presence of regional (p ≤ 0.001) metastases. SUVmax 
values were higher in hormone receptor negative, HER2 receptor positive, triple negative or 
high-grade tumors, and in patients with local lymphatic dissemination. A positive relationship 
was found between SUVmax and MIB-1 proliferation index (r = 0.573, p ≤ 0.001) and tumor 
size (r = 0.681, p ≤ 0.001) by Spearman’s correlation. The presence of distant metastases and 
histological type did not show significant association with SUVmax.
CONCLUSION: Our results are mainly in concordance with other studies. However, the litera-
ture is contradictory in the case of HER2 receptor status as many articles found no correlation 
between HER2 status and SUVmax. Our findings confirmed the theory that higher SUVmax 
is associated with bad prognostic factors.
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T5. PRECLINICAL STUDIES
T5-1
SYNTHESIS OF NOVEL 68GA-LABELLED 2-NITROIMIDAZOLE-NOPO 
RADIOTRACER FOR TUMOR HYPOXIA IMAGING
Barbara Gyuricza, Anikó Fekete, György Trencsényi, Dezsö Szikra
Medical Imaging Clinic, University of Debrecen
INTRODUCTION: Positron emission tomography (PET) is suitable for visualizing hypoxic 
regions in tumors. Tumor hypoxia can play essential role in malignant progression and resis-
tance to anticancer treatment. 2-Nitroimidazole-based radiopharmaceuticals are used for the 
imaging of hypoxia since 2-nitroimidazole derivatives accumulate in hypoxic cells. Recently, 
the use of the radiometal chelates as a radiotracer has been intensely investigated. The aim 
of this project is the preparation of the new 68Ga-labelled 2-nitroimidazole-NOPO radiotracer 
and to evaluate its potencial for tumor hypoxia imaging.
METHODS: Firstly, the commercially available 2-nitroimidazole was N-alkylated by 2-(t-butyloxy-
carbonylamino) ethyl bromide. After the removal of the t-butyloxycarbonyl protecting group the 
obtained 2-nitroimidazole derivative was coupled with NOPO chelating agent. The synthesized 
2-nitroimidazole-NOPO precursor was labelled with 68Ga, which was obtained from a 68Ge/68Ga 
generator. Solid phase extraction afforded the novel 68Ga-labelled 2-nitroimidazole-NOPO 
and the radiochemical purity was determined by radio-RP-HPLC. A small animal PET/MRI 
study was performed in a KB tumor-bearing and a BALB/c mouse. Images were obtained at 
90 mins after tail vein injection of radiotracer. 
RESULTS: We successfully synthetized a new 68Ga-labelled 2-nitroimidazole-NOPO radiotracer. 
According to PET/MRI study the 68Ga-labelled radiotracer uptake was intense. Mean SUV 
was 0.42 ± 0.04 and the tumor to muscle SUV ratio was 14 ± 1.38.
CONCLUSION: The preliminary biological study confirmed that 68Ga-labelled 2-nitroimid-
azole-NOPO could be a promising new radiotracer for the evaluation of tumor hypoxia.
T4-5
BIOLOGICAL THERAPY AND RADIOSYNOVIORTHESIS IN PATIENTS  
WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS
Margit Szentesi, Zoltán Nagy, István Papp, Pál Geher
Rheumatology and Physiotherapy, Semmelweis Univ., and Polyclinic of the Hospitaller 
Brothers of St. John of God., Budapest
INTRODUCTION: The treatment of patients with rheumatoid arthritis (RA) has been spectacu-
lary changed since the 1950’s. Introduction of the steroid compounds and their local application, 
the chemical and radionuclide synovectomy, surgical synovectomy, use of non-steroid drugs, 
the basic treatment and the spread of biological therapy are the most important steps. Introduc-
tion of the biological therapy has changed the quality of life for these patients.
OBJECTIVES: During biological therapy sometimes 1 or 2 joints could be affected by inflam-
mation. In this cases always the question is how to solve the problem. Change of the biological 
or basic therapy, use surgical synovectomy or radiosynovectomy (RSO)?
METHODS: In our reumatological department 2100 patients with RA and PA were treated 
with biological therapy between 2002 and 2015. In 100 patients we applied RSO because of 
the inflammation of the knee joint during biological therapy. We made a long term follow-up 
in 72 patient. 
All participants provided written informed consent. 
62 participants inflammatory knee joint disease was diagnosed on the basis of the American Col-
lege of Rheumatology. 55 of 62 patients with rheumatoid arthritis were seropositive, 7 seronega-
tive. Steinbrocker functional stadium II was observed in 52, stadium III in 10. 10 patients were 
psoriatic arthritis. Mean age of 11 male and 61 female patients was 51.4 years (range 24–79) 
years. In 38 patients the right knee, in 34 the left knee was treated by radiosynovectomy. Mean 
duration of disease was 7.3 years (range 0.5–25), of synovitis (6.3 month (range 3–8). Mean 
number of punctions of the treated joint prior to radiosynovectomy was 4.2 per patient and 
of steroid administrations prior to radiosynovectomy 3.0. In 12 patients a systemic steroid 
therapy has been performed. 
RESULTS: During the study period, inflammation decreased. In the first two years excellent and 
good results were recorded in 82.2%. Two years after radiosynoviorthesis 83.3% of patients did 
not need another punction. 
Before the knee inflammation patients were in complete remission which status has been 
achieved after RSO as well. DAS: 2.4 ± 0.4. 
CONCLUSIONS: 
1. RSO is an effective method to treat the inflammation of the knes.
2. The RSO performed during biological tehrapy is as effective as in the case of patients with-
out biological therapy. 
3. In case of a successful RSO there is no need for biological or basic therapy neither for 
surgical synovectomy. 
4. However an intraarticular injection has a low risk for infection it is recomended to avoid 
the biological therapy during the RSO. 
T4-4
TREATMENT OF METASTATIC PROSTATE CANCER PATIENTS WITH RA-223 
DICHLORIDE (XOFIGO)
Zita Képes1, Mónika Ilyés2, Ágnes Deák3, Alexandra Vánczku2, Anna Káplár2, 
Orsolya Sántha4, Judit Szegedi-Szabó2, Ildikó Garai1, 2 
1Division of Nuclear Medicine, Department of Medical Imaging, University of Debrecen 
2Scanomed Company 
3Faculty of Medicine, University of Debrecen 
4Diagnostic and Therapeutic Ward of Nuclear Medicine, Hospital of the County of Borsod-
Abaúj-Zemplén and the Teaching Hospital of the University of Debrecen
INTRODUCTION: Ra-223 dichloride is approved for the treatment of patients with castra-
tion-resistant prostate cancer suffering from symptomatic bone metastases and no evidence 
of visceral metastatic disease. Ra-223 dichloride is the first alpha-particle emitting radiothera-
peutic drug for systemic use. As calcium analogue, it forms complexes with hydroxyapatit 
crystals especially in the areas of increased bone turnover. In our study we analysed efficacy 
of the therapy on bone pain and on the survival of the patients treated with Ra-223 dichloride. 
METHODS: We treated 51 patients (mean age 68.51 year, 44–89 y) with 271 cycles of Ra-223 
dichloride therapy matching the approved inclusion criteria for the treatment. The mean follow-up 
period was 15 months (6–29 months). The time from the diagnosis of bone metastases to the 
therapy was mean 3.3 years (1–16 y). Every patient had at least 3 bone metastases especially 
in the axial skeleton. 50 kBq/kg Ra223 dichloride was administered iv. in 6 cycles, with 4-week 
intervals. During the follow-up we controlled the hematological status with lab tests and the 
intensity of the pain using 10-point visual scale. 22 patients got chemotherapy (Docetaxel) before 
Ra-223 therapy. All statistical calculations were carried out by IBM SPSS statistics software.
RESULTS: 36/51 patients completed 6 cycles of radioisotope therapy. We had to discontinue 
the treatment in 15 cases. The median overall survival after Ra-223 therapy was 11 months. 
Kaplan-Meier analysis proved that there is no significant difference in survival time between 
patients who underwent chemotherapy prior to Ra-223 therapy or did not (12 months vs. 
11 months). The significance was calculated by Breslow (Generalized Wilcoxon) test, p = 0.506. 
We could not find significant changes in laboratory parameters (Mann-Whitney test) during the 
therapy. Jonckheere-Terpstra test was applied to examine trends in pain response during the 
treatment. The p = 0.000 indicated the differences in pain (the median of pain value changed 
from score 6 to score 2).
CONCLUSION: Radium-223 dichloride is the first systematic a-emitter therapeutic agent 
that has shown significant benefits to soothe bone pain in prostatic cancer patients having 
bone metastases. 
T4-3
INICIAL EXPERIENCE WITH XOFIGO (223RaCl2) THERAPY 
Rita Német, Zsuzsanna Besenyi, László Pávics
Department of Nuclear Medicine, University of Szeged
INTRODUCTION: Prostate cancer is one of the most common malignant tumor in men. The 
disease prognosis is poor, metastases are common, which develop 85–90% in the bones. In 
bone involvement treatment the Ca analog 223RaCl2 (Xofigo) is the first alpha emitting product 
not only relieves bone pain, but also improves the overall survival of the patients.
METHODS: From August 2014 to February 2017, 30 patients were treated with Xofigo. 141 
times were given 223RaCl2 by us [mean activity was: 4.37 (± 1.3) MBq] Haematological param-
eters of the patients were tested before each treatment. For the first treatment patients arrived 
with medical referral and bone scintigraphy result. To follow-up the pain intensity changes the 
patients was asked to fill out a Visual Analog Pain Scale (Pain Assasment Scales, NIPCTM) 
each treatment. We compared the bone scintigraphy results of the patients, which were made 
within 3 months before and after the therapy.
RESULTS: There were no difficulties in the radiopharmaceutical preparation and injection. 
We followed the general rules of radiation safety, there wasn’t detected significant changes in 
background radiation by surface mesurments [the avarage value before treatment: 0,125 
(± 0.03) uSv, after treatment: 0,135 (± 0.03) uSv]. The 30 patients hematological parameters were 
monitored throughout the therapy. There were no significant changes in red blood cell, hemo-
globin and platelet counts. In the number of red blood cell 0.7 (± 0.18), T/L, in hemoglobin 
10 (± 4.56) g/L, and in platelet 90 (± 17.37) g/L average decrease was observed. Haematologi-
cal changes was slightly more significant in white blood cell and neutrophil granulocyte count, in 
white blood cell 3 (± 1.031) g/L, in neutrophil count 1.8 (± 0.6) g/L average decrease was ob-
served. 16 patient got the full six cycle treatment. Due to major haematological changes the 
therapy was suspended in 3 cases. In those cases when patient received less than 6 cycle from 
the treatment, the oncologyst or urologyst doctor indicated the treatment suspension by some 
other reason, which was not proven to associate with Xofigo therapy (like visceral progres-
sion). The bone pain intensity of the patients were gradually decreased during the treatment, 
most of the cases after the fourth cycle the bone pains were almost completely gone. Based 
on the numeric pain scale the pre-treatment mean value 6.4 (± 2) was decresed to 1.2 (± 1) 
post-treatment mean value. Comparing the pre and post therapy bone scintigraphy results of 
the patients, in most cases regression were occurred, means the number and/or the intensity 
of the bone metastases were reduced.
CONCLUSION: The alpha-emitting 223RaCl2 is safely used for the treatment of castration-re-
sistant prostate cancer with bone metastasis. Compliance with the general rules of radiation 
safety, increased background radiation was not observed. The condition of the patients usually 
were improved, their bone pains were decreased, almost in every case completely disappeared. 
Bone scintigraphy is suitable to follow-up the treatment effectiveness. 
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T6. CLINICAL NUCLEAR MEDICINE
T6-1
CARDIAC 18F-FDG PET/CT IN CONNECTIVE TISSUE DISEASES
Zsuzsanna Besenyi1, Gergely Ágoston2, Rita Hemelein3, Annamária Bakos1,  
László Kovács3, Albert Varga2, László Pávics1
1Department of Nuclear Medicine, University of Szeged 
2Department of Family Medicine, University of Szeged 
3Department of Rheumatology, University of Szeged
INTRODUCTION: Cardiac involvement is a common complication in connective tissue 
diseases particularly in systemic sclerosis (SSc). In SSc the immuno-inflamatory damage 
leads to myocardial fibrosis and consequent myocardial dysfunction. The development of overt 
myocardial manifestation is recognized as powerful adverse prognostic factor. 18F-FDG PET/CT 
has increasing role in inflammatory diseases with myocardial manifestation. The aim of this study 
was to assess the diagnostic utility of cardiac 18F-FDG PET/CT in patients with SSc, and to 
evaluate simultaneously results of 2Dimensional Speckle Tracking Echocardiography (STE).
METHODS: 17 patients with connective tissue diseases (13 patients with SSc and 4 patients with 
suspected arteritis, age: 57.3 ± 10, 13 female, 4 male) where enrolled in the prospective 
study. After low carbonhidrate-diet (previous 24 hours) and extended fasting (6 hours) cardiac 
18F-FDG-PET/CT acquisition was performed in 2D mode and short-whole-body in 3D mode. 
Within 24 hours all patients underwent comprehensive echocardiography focusing on left ven-
tricular myocardial mechanics applying STE. The recommended 17 segment model was used 
to assess the 18F-FDG activity and for the calculation of myocardial strain as well. On -FDG 
PET/CT the segmental myocardial 18-FDG uptake in kBq/cc by PMOD software was calculated. 
The strain values were measured offline by speckle tracking EchoPAC software. 
RESULTS: Among 17 patients 5 patients (29%) showed significantly increased 18F-FDG uptake 
(18.6 ± 6.8 kBq/cc vs. 7.77 ± 3.4 kBq/cc, p < 0.01) in the myocardium. In patients where 
the 18F-FDG uptake was increased, measured global left ventricular longitudinal strain val-
ues (19.4 ± 2.7% vs. 13.4 ± 8%, p < 0.01) was decresed. There was a negative correlation 
between myocardial strain and 18F-FDG uptake (p < 0.05, r = –0.54) In 4 patients with arteritis, 
the 18-FDG uptake was not increased (4 ± 0.2 kBq/cc), and left ventricular strain values were 
also in physiological range (21.5 ± 2%). 
CONCLUSION: 18F-FDG PET/CT is a promising imaging tool to detect myocardial manifes-
tation of SSc. In the active condition of the myocardial involvement STE provides a simple, 
non-invasive modality to detect subtle mechanical changes in myocardium.
T5-4
INVESTIGATION OF MSH RECEPTOR EXPRESSION USING GA-68-  
AND SC-44-LABELED MOLECULES
Gábor Nagy1, Adrienn Kis2, Noémi Dénes2, Judit P. Szabó2, Tamás Nagy2,  
István Hajdu2, István Kertész2, János Hunyadi3, Ervin Berényi2, Ildikó Garai1, 2, 
Dezsö Szikra1, 2, György Trencsényi*1, 2
1Scanomed Ltd., Debrecen 
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INTRODUCTION: Alpha melanocyte stimulating hormone (alpha-MSH) enhances melano-
genesis in melanoma malignum by binding to melanocortin 1 receptor (MC1R). Earlier stu- 
dies demonstrated that MSH analogues (e.g. NAPamide) specifically binds to MC1R receptor. 
Radiolabeled NAPamide is a promising radiotracer for the detection of melanoma tumors by 
Positron Emission Tomography (PET). In this present study the MCR1 selectivity of the newly 
developed Sc-44-labeled DOTA-NAPamide was investigated using melanoma tumors.
METHODS: MC1R positive (B16-F10) and negative (A375) melanoma cell lines were used. 
Cells (1 × 106/ml tube) were incubated for 30 or 60 min in the presence of 0.74 MBq of Sc-
44- or Ga-68-labeled DOTA-NAPamide. After the incubation time samples were washed and 
the radioactivity was measured with calibrated gamma counter. For the induction of tumor 
models 1 × 105 A375 or B16-F10 tumor cells were injected subcutaneously into the left 
shoulder area of CB17 SCID or C57BL/6J mice, respectively. For imaging studies mice were 
injected intravenously with 13 ± 1.2 MBq of Sc-44/Ga-68-labeled DOTA-NAPamide 15 ± 1 
days after tumor cell inoculation. 20-min static whole body PET scans were acquired 60 min 
after radiotracer injection using preclinical PET/MRI. Radiotracer uptake was expressed in 
terms of standardized uptake values (SUVs). 
RESULTS: In vitro and in vivo imaging experiments showed that Ga-68- and Sc-44-labeled 
DOTA-NAPamide specifically bind to MC1 receptors of B16-F10 cell and tumors. B16-F10 
cells showed significantly (p ≤ 0.01) higher in vitro radiotracer accumulation than that of 
A375 cells. In animal experiments, significantly (p ≤ 0.01) higher Ga-68-DOTA-NAPamide 
(SUVmean: 0.38 ± 0.02), and Sc-44-DOTA-NAPamide (SUVmean: 0.52 ± 0.13) uptake 
was observed in subcutaneously growing B16-F10 tumors, than in A375 tumors, where the 
SUVmean values of Ga-68-DOTA-NAPamide and Sc-44-DOTA-NAPamide were 0.04 ± 0.01 
and 0.07 ± 0.01, respectively. We found that the tumor-to-muscle (T/M SUVmean) ratios were 
approximately 15-fold higher than the T/M ratios of A375 tumors, and this difference was also 
significant (p ≤ 0.01) using both radiotracers. No difference was observed between Ga-68- and 
Sc-44-labeled DOTA-NAPamide uptakes.
CONCLUSION: The investigated Sc-44-labeled DOTA-NAPamide, as a newly developed PET 
radiopharmaceutical specifically binds to MC1 receptors of melanoma cells. Due to its high 
specificity Sc-44-DOTA-NAPamide is a promising PET radiotracer for the detection of mela-
nocortin 1 receptor positive melanoma tumors in the clinical routine.
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INTRODUCTION: Aminopeptidase N (APN/CD13) plays an important role in neo-angiogenic 
process and metastatic tumor cell invasion. Our previous studies have already shown that 
68Ga-labelled NGR peptides specifically bind to APN/CD13 expressing tumor cells. The 
68Ga labelled NGR peptides were enabled to investigate the neo-angiogenic process with 
Positron Emission Tomography (PET). The aim of this study was to investigate and compare 
the 68Ga-NOTA-c(NGR), 68Ga-NODAGA-NGR (tioether) and 68Ga-NODAGA-NGR (sarcosine) 
specificity of APN/CD13 in hepatocellular carcinoma (He/De) and mesoblastic nephroma 
(Ne/De) tumor models using PET/MRI.
Methods: He/De (hepatocellular carcinoma) and Ne/De (mesoblastic nephroma) cells were 
used for the induction of heterotopic transplanted [subcutaneously (n = 4) and under the left 
kidney capsule (n = 4)] tumor models in Fischer-344 rats. Whole body PET/MRI (nanoScan 
PET/MRI, Mediso Ltd, Hungary) scans and ex vivo biodistribution studies were performed us-
ing tumor-bearing and control (n = 3) animals 90 min after intravenous injection of 6.9 ± 0.2 
MBq 68Ga-NOTA-c(NGR) or 68Ga-NODAGA-NGR (tioether) or 68Ga-NODAGA-NGR (sarcosine) 
and two weeks after tumor cell implantation. The imaging of neoangiogenetic process with 
68Ga-NOTA-c(NGR) was compared with 68Ga-NODAGA-NGR (tio) and 68Ga-NODAGA-NGR 
(sar) tracer. Aminopeptidase N receptor expression of He/De and Ne/De tumors was verified 
by western blot analysis. 
Results: In control animals using 68Ga-NOTA-NGR high SUVmean values were observed in 
abdominal organs, however, in the case of 68Ga-NODAGA-NGR (tio) and 68Ga-NODAGA-NGR 
(sar) it was much higher. SUVmean and Tumor/Muscle(SUVmean) ratios were found higher 
after injection of 68Ga-NOTA-NGR, than the administration of 68Ga-NODAGA-NGR (tio) or 
68Ga-NODAGA-NGR (sar) in Ne/De tumor bearing animals. In the case of He/De tumor bear-
ing animals comperable SUVmean and Tumor/Muscle(SUVmean) values were detected. 
Higher SUVmean and Tumor/Muscle(SUVmean) ratios were measured after the injection of 
68Ga-NOTA-NGR, than after that of the 68Ga-NODAGA-NGR (tio) or 68Ga-NODAGA-NGR (sar). 
The APN/CD13 receptors attendance was demonstrated with Western blot analysis.
Conclusions: Among the investigated radiopharmacons the 68Ga-NOTA-c(NGR) showed 
the highest binding affinity to APN/CD13 positive tumors by PET/MRI imaging. Therefore, 
68Ga-NODAGA-NGR (tio) showed sufficient and 68Ga-NODAGA-NGR (sar) showed the worst 
properties for the detection of APN/CD13 expression. 
This project was supported by the János Bolyai Research Scholarship of the Hungarian 
Academy of Sciences.
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Introduction: Malignant melanoma is the most aggressive form of skin cancers. Although, only 
3–5 percent of the skin cancer is melanoma, it possesses the worst prognosis. Nowadays one of 
the most efficient methods in tumor diagnostics is PET imaging; several recent studies focus on 
the development of melanoma specific tracer. Previous researches have shown that benzamide 
derivatives were proven to be specific markers for detection of melanoma. The aim of this study 
was to radiolabel the NODAGA and HBED-CC chelator conjugated PCA derivative with Ga-68, 
and in order to PET imaging, to apply the labeled compounds on animal models of melanoma. 
Moreover, we aimed an extensive testing of the compounds under in vitro and in vivo conditions. 
Methods: The procainamide was conjugated with NODAGA and HBED-CC chelators. 
The complete ligands were purified with RP-HPLC and then were lyophilized. The product 
was characterized by ESI-MS and 1H-NMR. The 68Ge/68Ga generator (Eckert-Ziegler, Obninsk) 
was eluted by using 0.1 M with 5 mL HCl. The labeling was accomplished on pH = 4.5–4.6 
in NaOAc buffer at room temperature and at 95 °C for five minutes. The melanin specificity 
of 68Ga-HBED-CC-PCA and 68Ga-NODAGA-PCA was investigated in vitro and in vivo using 
amelanotic (MELUR and A375) and melanin containing (B16-F10) melanoma cell lines. 
Tumour-bearing animals were prepared by subcutaneous injection of B16-F10, MELUR and 
A375 melanoma cells into C57BL/6 (n = 10) and SCID (n = 9) mice.
Results: Procainamide derivatives conjugated with two different chelators were prepared suc-
cessfully. The compounds possessed excellent radiochemical purity (≥ 98%). The octanol-PBS 
partition coefficients (LogP) of the two radiolabeled compounds were determined. Based on the 
results of the in vitro measurements the 68Ga-NODAGA-PCA showed significantly (p £ 0.01) 
higher accumulation than the 68Ga-HBED-CC-PCA on the B16-F10 cell line. 
Conclusion: Two 68Ga labelled PCA derivatives were developed, which could selectively 
accumulate in melanin producing melanoma cells. The uptake values of the compounds are 
diverse and the in vivo preclinical measurements have confirmed, that the 68Ga-NODAGA-PCA 
possessed higher uptake on tumour models. Therefore, it was proven that the heterobifunctional 
chelators also served as pharmacokinetic modifiers, and by their selection the distribution profile 
of the radioligands within the organism can be considerably modifiable.
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INTRODUCTION: Dynamic ventilation scintigraphy (DIT) has proved to be a suitable method 
for the staging and follow up of the damages of alveolo-capillary membrane (ACM) system of 
the lungs. The e-cigarette is a new smoking device producing vapor from nicotine solution. 
Here we present comparative DIT results of e-cigarette users, who returned for one week to 
traditional cigarette smoking.
METHODS: We included 24 healthy man volunteers (age 20–64) in the study, who regularly 
used e-cigarette, containing 10 or more mg nicotine/mL concentration fluid. First we acquired 
a baseline DIT study, calculating the separate clearance half time (CT1/2) values of the lungs, and 
performed respiration tests (FVC, FEV1, PEF, FEV1/FVC) as well as measured CO and COHg 
concentrations from exhaled air at e-cigarette use. Then we asked the volunteers to return to 
traditional cigarette smoking for a week’s period. After that we repeated the above-mentioned 
tests, and statistically compared the results, using paired t-test for normally distributed variables, 
and Wilcoxon’s test for the rest.
RESULTS: There was no significant change in the results of PEF and FEV1/FVC respiration 
tests; FVC and FEV1 slightly decreased (p < 0.05), while the exhaled CO and COHg lev-
els were significantly higher at cigarette use (p < 0.0001), and increased in every case (CO: 
from a median value of 2 by 13 ppm; COHg: from a median value of 1.0% by 2.05%). The 
DIT CTl/2 times were lower at traditional cigarette smoking compared with e-cigarette use in 
every case (p < 0.001, Wilcoxon test): from 66.7 ± 24.3 min decreased by 31.1 ± 16.1 min), 
to 51.4% (median) of the base value.
CONCLUSION: We first compared at the same persons the direct effect of traditional smok-
ing vs. e-cigarette upon the lung ACM. Our results confirmed the known toxic (especially CO) 
effect of traditional cigarette smoking causing persistent alveolitis. The normal CT1/2 values at 
e-cigarette use prove that it has no similar effect, there is no sign of alveolitis. So it could be 
recommended for heavy smokers who are unable to stop smoking, to switch to e-cigarette 
use, which is more tolerable for the lungs, for the ACM.
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INTRODUCTION: Our goal was to research our institution’s patients’ diagnostic value of 
combined 99m Tc-pertechnetate- and 99m Tc-MIBI scintigraphy in determining the malignant 
nature of thyroid nodes.
METHODS: Our retrospective investigation included any patient examined with 99m Tc-per-
tenchnetate- and/or 99m Tc-MIBI scintigraphy from 2009 to 2012 in our institution, a total of 650 
(104 male, 546 female; avarage age = 54.55 yrs, SD = 14.38 yrs). We evaluated the number 
of patients showing increased nodular 99m Tc-MIBI uptake or missing uptake. Patients with 
normal or higher 99m Tc-pertechnetate nodular uptake were excluded, resulting in a group 
of 524 (81 male, 443 female; avarage age = 54.22 yrs, SD = 14.77 yrs). We calculated the 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and 
diagnostic accuracy (DA) of 99m Tc-MIBI scintigraphy for malignant thyroid diseases in 
case of 99m Tc-pertechnetate cold nodules. The malignancy of the evaluated thyroid nodule 
was confirmed by histological and/or citological diagnosis. The aquired data was processed 
in light of age groups and gender.
RESULTS: Thyroid surgery and/or FNAB (Fine Needle Aspiration Biopsy) was perfromed 
in 228 of the cases (28 male and 200 female; avarage age = 52.088 yrs, SD = 11.394 yrs). 
Out of the 524 patients, 152 had shown increased 99m Tc-MIBI nodular uptake (hot nodule). 
Out of the 228 cases with pathological diagnosis, 121 cases showed hot nodules on 99m 
Tc-MIBI scintigraphy. Out of the 20 malignant thyroid tumors, 17 showed high, 3 showed low 
MIBI uptake. In case of cold pertechnetate nodules 99m Tc-MIBI had a sensitivity of 85.00%, 
specificity of 50.48%, a PPV of 14.17%, a NPV of 97.22%, and a DA of 53.5%. We found that 
age and gender did not affect these values except for PPV, in which case the avarage age 
(M = 54.447 yrs, SD = 13.332 yrs) of false positive patients was significantly higher than for 
true positive patients (M = 47.529 yrs, SD = 18.648 yrs, p = 0.022).
CONCLUSION: Our results confirmed that the main use of 99m Tc-MIBI scinigraphy in case 
of 99m Tc-pertechnetate cold nodules, is the exclusion of malignancy. A positive MIBI scan 
can not determine the need for surgical intervention. Although in younger patients the PPV of 
the examination is the highest, it does not exceed 50%.
T6-3
EVALUATION OF 18-FDG PET/CT IN DIAGNOSIS OF LARGE VESSEL 
VASCULITIS
Annamária Bakos1, Zsuzsanna Besenyi1, Szabolcs Urbán1, Rita Hemelein2,  
László Kovács2, László Pávics1
1Department of Nuclear Medicine, University of Szeged 
2Department of Rheumatology, University of Szeged
INTRODUCTION: Large vessel vasculitis (LVV) is a group of granulomatous inflammatory 
diseases and includes the giant cell arteritis (GCA) and Takayasu arteritis (TA). The increased 
inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) and the clinical 
signs are not specific for LVV, and not always congruent with disease activity. The early 
diagnosis and treatment is essential to avoid the late complications. 18-FDG accumulates in 
activated inflammatory cells, and has superior sensitivity for the detection of vasculitis in early 
stage of disease and for evaluating therapeutic response. The PET/CT method provides better 
anatomical localisation. The aim of this study was to diagnose vasculitis in new cases and 
to reveal relapses.
METHODS: 24 patients (17 females, 7 males, mean age: 61 years) were involved into the study 
from 2015 December. The patients were selected from the Department of Rheumatology. The 
18-FDG PET/CT was performed to diagnose primary in 19 cases and to evaluate the relapse 
in 5 cases. We included cases with increased inflammatory markers, non-specific clinical 
symptoms (weightloss, fever, malaise) and suspicious clinical symptoms: extremity claudica-
tion, chest-abdominal pain, visual disturbance, jaw claudication, headache, temporal artery 
tenderness, swelling, proximal myalgia). 18-FDG PET/CT images were evaluated visually by two 
nuclear medicine physicians, in consensus, who were blinded to clinical and laboratory data. 
RESULTS: 18-FDG PET/CT revealed LVV in 6 (6/19) patients as primary diagnosis. PET/CT 
proved extensive LVV in one patient who had arteritis temporalis as clinical diagnosis, the 
18-FDG uptake was increased in the following arteries: in the thoracic aorta and major branches, 
in the abdominal aorta, bilateral common iliac, bilateral external iliac and bilateral femoral arter-
ies. We detected relapses in 2 patients who were previous diagnosed as LVV. The changing 
of clinical features after therapy correlated with the PET/CT diagnosis.
CONCLUSION: 18-FDG PET/CT has important relevance in diagnosis of LVV and is effective 
in monitoring response to therapy. This hybrid modality is able to identify tissue metabolic 
changes besides anatomic localisation.
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INTRODUCTION: Duodopa treatment may be effective for patients with advanced stage 
Parkinson’s Disease (PD), in case of good response to Levodopa therapy and the combina-
tions of the available convencional antiparkinson medicaments doesn’t provide the expected 
results. The aim of the present study is to prove the importance of the visual and quantitative 
evaluation method of 123-I-Ioflupane (DaTSCAN, GE Healthcare) examination in determining 
the advanced stage of PD and the necessity of the Duodopa procedure.
METHODS: Duodopa treatment ensures a consistent level of Levodopa in the blood consider-
ing the current circumstances as well. Examinations were performed for 16 patients diagnosed 
severe PD based on clinical symptoms they were waiting for Duodopa treatment and in other 
24 patients who were diagnosed PD or Parkinson’s Syndrome (PSP, MSA). During the visual 
evaluation a well-establised (Benamer HTS, P. J. 2000) visual scale was applied (normal, 
abnormal grade I, II, III) by two independent experts. During the quantitative evaluation the 
patientes CT and MRI pictures were registered and MRI mask was used on the SPECT image 
in the different regions.
RESULTS: There was considerable agreement between the visual scores given by the two 
observers and the visual score correlated with the clinical stage of PD. In case of patients await-
ing Duodopa treatment there was substantial agreement between the two independent observ-
ers (k = 0,625, p = 0,04). Severe PD was confirmed with a sensitivity of 100% and specificity of 
54% by one of the observers, and it was determined with a sensitivity of 100% and specificity 
of 42% by the other observer. There was a significant difference between the distribution of the 
visual grade of the two groups of patients, because of two observers provided higher grade 
(II., III) in patients with Duodopa therapy than the other group. There was also a similar correlation 
considering the Hoehn and Yahr scale. The mean count of VOI putamen — with lower specific 
uptake ratio — was compared with the mean count in VOI occipital cortex was significantly 
lower in case of both evaluating methods in patients with PD before Duodopa therapy than 
the other group of the patients. Duodopa patients had been diseased for significantly longer 
period than the others.
CONCLUSION: Both the visual and quantitative methods support the differenciation of the 
various stages of PD. Visual technique is an appropriate way to confirm the advanced stage of 
PD, which can be proved by quantitative parameters of the objective method. We expect that 
DaTSCAN examination will be able to help in predicting the efficiency of Duodopa treatment.
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INTRODUCTION: Effect of storage in disposable polyethylene/polypropylene (PE/PP) syringe 
was studied on the quality of Nanoscan 500 micrograms radiopharmaceutical in order to sup-
port economical clinical radiopharmaceutical usage.
METHODS: Samples (n = 5) were taken from 99mTc-isotope labelled Nanoscan radiophar-
maceutical (Medi-Radiopharma) into disposable PE/PP syringes (B.Braun) and stored for 
10 hours at room temperature. The quality control of radiopharmaceutical in syringe was evalu-
ated by using thin-layer chromatography (TLC), particle size distribution (dynamic light scat-
tering, DLS) according to pharmacopeia and SmPC of the manufacturer. Measurements were 
done in every 2 hours after labelling until 10 hours. TLC method was performed on ITLC-SG 
layer in methyl-ethyl-ketone and saline 0.9%. Developed TLC layers were evaluated by using 
miniGita TLC scanner (Raytest), colloidal size distribution by using Zetasizer ZS (Malvern). 
Syringe retention was also measured with dose calibrator (Isomed 2010). Standard bioassay 
was executed in Wistar rats administered Nanoscan radiopharmaceutical, which has been 
stored in disposable syringes. Whole-body mapping was performed by using Nucline gam-
macamera (Mediso), organ activities were measured with 2480 Wizard2 automated gamma 
counter (Perkin Elmer). 
RESULTS: Chromatography for unbound, free pertechnetate showed no impurity neither in case 
of samples from ampoules nor samples from syringes at any time points. TLC for non-colloidal, 
soluble species resulted in no difference between samples from glass vial and PE/PP syringes at 
any time points, and all the results (0.0–0.4%) met requirements of the pharmacopeia and 
the SmPC. Mean colloidal size (15.5–16.0 nm) and polydispersity (PdI = 0.33–0.44) mea-
sured with DLS method showed no changing tendency in the investigated time interval. No 
change was observed in syringe retentions (8.3 ± 0.5%) during the storage up to 10 hours. 
No difference was found in biological distribution of Nanoscan radiopharmaceutical stored 
in disposable PE/PP syringes compared to the distribution of radiopharmaceutical stored in 
its glass ampoule when bioassay were performed in rats. There was no result from any of the 
applied methods which differed between samples stored in its own glass ampoule and in 
disposable PE/PP syringes in the investigated 10-hour time period.
CONCLUSION: Storage in disposable PE/PP syringes had no influence on the quality of 
Nanoscan product, consequently radiopharmaceutical stored in PE/PP syringe passed phar-
macopeial requirements up to 10 hours.
Support was provided by „Kincstári Monitoring Rendszer” KMR_12-1-2012-0057.
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INTRODUCTION: A growing demand arises by clinical users for easy-to-handle, rapid tests for 
quality control of radiopharmaceuticals after labelling. In our experiments we compared 
easy-to-handle, quick tests to pharmacopeial radiochemical purity method.
METHODS: Renoscint-MAG3 (Medi-Radiopharma) preparations were labelled with 99mTc 
isotope in the maximal activity concentration according to the manufacturer’s instructions. Thin 
layer chromatography (TLC) and solid phase extraction (SPE) methods were performed and 
compared to pharmacopeial radio-HPLC method (PhEur). Ethyl acetate: butanone or water: 
acetonitrile mobile phase were applied on TLC layers (ITLC-SG or GMCP-SA or Whatman 
3 mm). Evaluation of developed layers were done by using miniGita TLC scanner (Raytest). 
SPE was performed on SepPak C18 cartridge (Waters) with hydrochloric acid, phosphate 
buffer and ethanol as eluents. The activity of the factions were measured with dose calibrator 
(Isomed 2010). The reference method was performed using Agilent 1200 HPLC system with 
Gabi flow through radiodetector (Raytest).
RESULTS: The solid phase extraction showed 0.6 to 1.3% lower radiochemical purity (RCP) 
results than those of radio-HPLC method. The amount of hydrophilic impurities correlated well 
as measured by using the two methods (SPE and HPLC). Difference of RCP results came from 
the amount of lipophilic impurities. The amount of hydrophilic impurities separated on instant 
thin layers (ITLC-SG, -SA) were similar to those of HPLC reference method. Evaluated the two 
type of layers the ITLC-SG method gave a more efficient separation and approached better 
the results of the reference method (difference +0.3–0.9% compared to the HPLC method). 
Reduced hydrolyzed technetium colloids were not detected on the Whatman 3 mm layer.
CONCLUSION: Improving the efficiency of the elution of 99mTc-mertiatid (MAG3) fraction might 
optimize the separation. Using ITLC-SG layer in ethyl acetate: methyl ethyl ketone mobile phase 
for determination of hydrophilic impurities is more accurate and efficient than using GMCP-SA 
layer. All the quick tests (TLC and SPE) resulted in radiochemical purity results that meet the 
requirements of the pharmacopeia and the SmPC. All the investigated quality control quick 
tests are suitable for rapid quality checking of Renoscint-MAG3 after labelling at clinical site 
as compared to reference pharmacopeial radio-HPLC method.
Support was provided by „Gazdadságfejlesztési Operatív Program” GOP-1.1.1-11-2011-0021.
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INTRODUCTION: 11C labelled tracer molecules are often used in PET examination. In most 
cases the labeling procedure is methylation with [11C]methyl-iodide reagent. We applied the 
Tracer Maker synthesis panel developed by Peter Larsen to produce [11C]MeI and [11C]
Me-Triflate in order to synthesize [11C] isotope labeled radiotracers. Our objective was to 
optimize parameters of synthesis panel.
METHODS: We produced [11C]MeI by the gas phase method using the Tracer Maker synthet-
sizer. [11C]CO2 generated in the target was reacted with H2 at 360 °C in the presence of Ni 
catalyst. The resulting [11C]CH4 was separated from the waste gases by freezing at –190°C 
on Hayesep adsorbent. Upon heating the Hayesep the [11C]CH4 was released at –10°C and 
directed to the recirculating circuit containing an iodine column where methane reacted with 
the sublimated iodine vapours at 720°C. The formed [11C]MeI was adsorbed on Hayesep 
again, and released by heating to 200°C.
The operational parameters of the module were systematically varied in order to find those, 
which are influencing the yield. The pressure drop in the system was minimized using a multi 
stage leak-check program. We determined the decay corrected radioactivity produced in the 
cyclotron with 44 μA beam current and 2 minute irradiation time. The activity of the produced 
[11C]MeI with the same parameters was compared to this value. We varied the time of the 
regeneration of the adsorbents, the flow rate of the target gas, the temperature of the iodine 
and the high temperature furnace and the flow rate of the recirculation circuit. in order to study 
the dependence of the yield on these parameters.
RESULTS: The activity of the [11C]CO2 produced by the cyclotron was 12 GBq in our 
measurements. The initial yields of the system with default settings were 36 ± 3%. With the 
increase of temperature of the iodine oven only 2% increase was achieved. We observed no 
change in yield by increasing the flow rate of the recirculation circuit and the temperature of 
the high temp. oven. Optimization of the target gas flow, increase of the regeneration time, 
achieving appropriate starting temperature and minimizing pressure drops of each stages of 
the process resulted in a 52 ± 2% [11C]MeI yield. The radiochemical purity was more than 98%.
CONCLUSION: Based on our measurements, the critical part of the synthesis pro-
cess was found to be the adsorption of the [11C]CO2 on the molecular sieve. The other 
parameters showed only minor effect on the yield. 
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DEVELOPMENT OF SOLID TARGET AND PURIFICATION  
FOR THE PRODUCTION OF SCANDIUM-44
István Hajdu1, Viktória Forgács1, Anikó Fekete1, Enikö Várhalminé Németh1,  
Dezsö Szikra1, 2
1Division of Nuclear Medicine, Department of Medical Imaging, University of Debrecen 
2Scanomed Ltd., Debrecen
INTRODUCTION: Scandium-44 (44Sc) is a promising radionuclide that has favorable half-life 
(t1/2 = 3,97 h) and decay characteristics (Eb
+
av = 632 keV) for PET imaging. Currently, natural 
calcium or enriched calcium carbonate-graphite powder mixture is used as target material to 
produce 44Sc. Our goal was to develop a solid target and compare two novel separation method 
to obtain 44Sc in cyclotron from the proton irradiation of natural calcium target.
METHODS: The irradiated calcium target was dissolved in 3 molar hydrochloric acid and 
purified with syringe filter or ion exchange resin (DGA). Filter purification: 400 µL crude 44Sc 
solution was mixed with 800 µL 3%-ammonia solution to adjust the pH to > 10. Thereafter the 
entire solution was passed through 0.22 µm filter to trap 44Sc in colloidal form. To wash out 
the impurities, 5 mL water was passed through the filter. 44Sc was eluted with 0.1 molar HCl. 
DGA purification: the crude 44Sc solution was loaded onto the DGA column. To remove the 
impurities, 3 molar HCl and 1 molar HNO3 was passed through the column. 
44Sc was eluted 
with 0.1 molar HCl. The labeling efficiency of 44Sc was tested with different concentration of 
DOTA solution and NODAGA-AMBA peptide.
RESULTS: In case of filter purification 30.9 MBq activity was loaded onto the filter. The trapped 
activity was 29.5 MBq and 29.3 MBq remained after the washing. Eluted activity was 25.5 MBq in 
0.1 M HCl. The labeling test was < 95% by 1 micro molar DOTA solution but the yield was only 
17.5% using NODAGA-AMBA peptide. In case of DGA purification 115 MBq activity was loaded 
onto the filter. The trapped activity was 114 MBq and 109 MBq remained after the washing. 
Eluted activity was 89.3 MBq in 0.1 M HCl. The labeling efficiency was < 98% by 1 micro molar 
DOTA solution and the yield was 85% using NODAGA-AMBA peptide.
CONCLUSION: 44Sc was successfully produced and purified for peptide labeling. In our next 
step, we are planning to use enriched calcium carbonate that is necessary to produce isotopi-
cally pure 44Sc and allowing its use for clinical PET imaging.
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RADIOIODINE THERAPY FOR TREATMENT OF BENIGN THYROID DISEASES  
— A 14 YEAR RETROSPECTIVE ANALYSIS
Zsófia Patkó1, Barna Bakó2, Elvira Kócsák1, János Gombos1
1Department for Nuclear Diagnostics and Therapy, Borsod County University Hospital 
2Department for Internal Medicine, Borsod County University Hospital
INTRODUCTION: Over the past seven decades radioiodine has been a choice of treatment for 
thyroid diseases. However, dose estimation for optimal therapeutic outcome remains challeng-
ing. In our study we analyzed data from patients treated with radioiodine for benign hyperthyre-
oidism between 2002 and 2015 at the Department for Nuclear Diagnostics and Therapy, Borsod 
County University Hospital. The purpose of our study was to review effectiveness of radioiodine 
therapies applied at our department and draw consequencies for future therapeutic protocols.
METHODS: Altogether 160 patients (20 men and 140 women, age 54.4 ± 25) undergoing 
radioiodine treatment in our department between 2002 and 2015 were evaluated. Indications for 
therapy were Graves-Basedow (86%), Plummer’s disease (5%) and autonomic adenoma (9%). 
Inclusion and exclusion criteria were determined according to national and EANM guidelines. 
The primary aim of therapy was to terminate hyperthyreoidism. We used iodine uptake stud-
ies and Marinelli formula to estimate optimal dose for radioiodine therapy, the applied dose 
varied between 70 and 150 Gy (average: 81) in Graves disease and between 100 and 300 
Gy (average: 134) in cases of toxic adenoma. Searching our clinical database and following 
patients we scanned treatment success at 1 year and development of hypothyreoidism dur-
ing the follow-up period. We evaluated correlations between uptake studies, administered 
doses and therapeutic outcome.
RESULTS: We could trace patients for ca. 2–5 years after treatment and analyzed thyroid 
status, additional treatments and clinical outcome. At the 1 year follow-up visit, hypothyreo-
sis has been already diagnosed in 23%, and 35% of patients were euthyroid. One year after 
treatment hyperthyreosis persisted in about 30% of patients which was significantly reduced 
(to 5%) during the follow up period (2–5 years). Retreatment was needed in 15 cases (9%).
CONCLUSION: Radioiodine therapy is an effective alternative treatment for benign hyperthy-
reoidism, with a 95% cure rate in our department. Additional laboratory data and uptake stud-
ies as well as patient history may be useful to choose the accurate dose for radioiodine therapy.
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XOFIGO THERAPY NEEDS INTERDICIPLINARY COOPERATION
Róbert Péter Jóba, Sándor Czibor, István Szilvási
Magyar Honvédség Egészségügyi Központ, Budapest
INTRODUCTION: 223Radium dichloride (Xofigo) is an effective therapeutic tool for patients with 
symptomatic multiple bone metastasis of castration-resistant prostate cancer (mCRPC) without 
soft-tissue metastasis. Several clinical trials are going on to define optimal pretreatment clini-
cal criteria for the most effective („personalized”) use of Xofigo in the dynamically changing 
therapeutic stage.
PATIENTS: Various clinical data of our first 21 patients with mCRPC were analysed before, 
during and after Xofigo treatment. 7 patients had previous chemotherapy (docetaxel). 
Treatment had to be finished after one to three injections in 4 patients because severe granulo- 
and/or thrombocytopenia. In 3 patients Xofigo therapy was temporarily suspended due to 
reversible cytopenia (but continued 6–8 weeks later). Xofigo treatment was finished in two 
patients (due to newly developed brain metastasis and relapsed peptic ulcer respectively) and 
in other two patients with suspected radical nerve compression. These two patients presented 
severe ischialgia and neurological symptoms. Both patients had the same symptoms in their 
history long years before. We indicated MRI examination, and in both cases radical nerve 
compression was found. 13 patients had the full course of Xofigo treatment. The average 
number of injections was 4.53 per patient. The median follow-up period was 4.54 ± 3 months. 
No death occurred during the treatment and the follow-up.
METHODS: Bone pain was monitored by a subjective scoring system. Hemoglobin, absolute 
number of granulocytes and thrombocytes were measured not in every four, but in every sec-
ond week during the Xofigo treatment The serum level of prostate-specific antigen (PSA) and 
alkaline phosphatase (SAP) were measured before and in every eight weeks during and after 
the treatment. In all 13 patients with full cycle of treatment bone scintigraphy was performed 
before and 6–8 weeks after the last injection of Xofigo.
RESULTS: Xofigo-induced critical cytopenia occurred more frequently in patients with previ-
ous chemotherapy. In 18 out of 21 patients (and in all 13 with full course) bone pain has sig-
nificantly decreased. Serum PSA level was slightly increased during the treatment periode with 
exception of 2 patients. SAP level tended to be decreasing continuously, however, it started to 
rise again in the follow-up period. Bone scintigraphy demonstrated diminishing of abnormally 
increased focal osteoblastic activity.
CONCLUSIONS: Our first experience with Xofigo treatment underlines the importance of 
detailed knowledge of the history of patients before the planned Xofigo therapy. Close interdis-
ciplinary cooperation is important not only with the uro-oncologists. In patients with previous low 
back pain and neurological symptoms in the history, neurological examination and MRI have 
to be performed. Previous chemotherapy seems to be increase the risk of interrupting Xofigo 
treatment. In patients with well-tolerated Xofigo treatment a second course of Xofigo might be 
indicated to increase the quality of life and possibly overall survival.
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MICROBIOLOGICAL TESTING OF ASEPTIC EXTEMPORANEOS PREPARATION 
OF GALLIUM-68-PEPTIDE CONJUGATES WITH MEDI-MEDIA-FILL KIT IN 
NUCLEAR MEDICINE LABORATORIES
Klára Németh1, Gergely Jánoki1, Zsolt Mike2, Gyözö Jánoki2
1Radiopharmacy Laboratory Ltd., Budaörs 
2Medi-Radiopharma Co.Ltd., Érd
INTRODUCTION: The nuclear medicine laboratory should garantee the sterility and low 
bacterial endotoxin content of parenteral radiopharmaceuticals according to the current good 
practice for radiopharmaceuticals production. The microbiological purity can only be assessed 
after the administration of radioactive material, so exact knowledge of the aseptic preparation 
and its microbiological monitoring is of key importance. It can predict the microbiological purity 
of the radiopharmaceuticals prospectively. Our aim was to examine the aseptic preparation 
of the Ga-68-DOTA-TOC conjugate by previously developed microbiological quality control 
kit, MEDI-MEDIA-FILL kit.
METHODS: Before starting the preparation the aseptic environment must be ensured by 
sanitation (cleaning and disinfection). The microbiological contamination was checked by 
solid microbiological culture media TSA contact plates. During the aseptic preparation the 
media-fill method was applied, the aseptic process was carried out by a general microbial 
broth, TSB solution. The Ge-68/Ga-68 generator elution, the radiolabelling, the dilution and 
the sterile filtration were simulated. At each step samples were taken from TSB solution and 
incubated at 23 °C and 32 °C for 14 days as prescribed. The working surfaces and the operator 
were also sampled by contact plates at the end of the preparation, and the test plates were 
incubated at 23 °C to 32 °C for 5 days. 
RESULTS: The sanitation was considered adequate if there was no visible colonies on agar 
plates (< 1 CFU/sample) after the incubation. The aseptic procedure was appropriate if TSB 
solution was a clear fluid indicating sterility. Turbidity of TSB solution observed by necked eyes, 
and the colonies grown on agar plates indicated some microbial contamination because of 
incorrect aseptic preparation, insufficient sanitation procedure, or inadequate personnel hy-
giene. The microbiological tests were performed in three independent repeats in accordance 
with the validation requirements.
CONCLUSION: Application of the media-fill method in nuclear medicine laboratory can ensure 
the safe preparation of parenteral products, because it can help to estimate the microbiological 
risks and troubleshoot the hygiene risks. The method can be also applied for the professional 
staff‘s regular education, job training and checks required to work well. Documented good 
results obtained with MEDI-MEDIA-FILL kit and its supply kits in these studies can demon-
strate the proper operation of the laboratory for the authorities, and the existance of safety 
standards in healthcare.
Acknowledgements: Scientific work was supported by European and Hungarian project No 
GINOP-2.1.7-15-2016-00744. 
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EFFECT OF CHOLESTEROL RICH DIET ON TUMOR GROWING
György Trencsényi1, 2, Adrienn Kis1, Noémi Dénes1, Judit Péliné Szabó1,  
Tamás Nagy1, Ildikó Garai1, 2, Dezsö Szikra1, 2, István Hajdu*1
1Division of Nuclear Medicine, Department of Medical Imaging, University of Debrecen 
2Scanomed Ltd., Debrecen
INTRODUCTION: In developed countries, the most common cause of death are cardiovas-
cular disease and cancer. In our opinion the high cholesterol level increases the risk of cancer. 
Our research goal was to create dyslipidemic tumor bearing rat model which is suitable for 
investigating malignant tumors and hypercholesterinemia quickly and safely at the same time.
METHODS: Adult Fischer-344 and Long-Evans rats were used for the experiments. Rats were 
divided into control groups and Ne/De or My1/De tumor bearing groups. During the experi-
ments two different diets were used. 1: Standard diet, 2: Cholesterol rich diet. In one part of the 
test, beginning of the diet was equal to the time of tumor transplantation. In the other part of 
the test, the diet started two weeks earlier to the time of tumor transplantation. Two weeks after 
transplantation whole body 18F-FDG-PET/MRI scans were performed and tumor existence, size 
and 18F-FDG enhancement were determined. After the imaging rats were sacrificed, healthy 
kidneys and tumor bearing kidneys were removed and weighted. Blood samples were taken 
and lipid profile was determined from the serum.
RESULTS: Using cholesterol rich diet the total cholesterol level increased eight times, the LDL 
level increased thirty times, the HDL level increased four times the triglycerides level increased 
eight times. Weight of left kidney (3.36 ± 1.05 g) showed significant difference from right kidney 
(1.07 ± 0.25 g) in My1/De tumor bearing rats fed with standard diet. Tumor bearing left kidney 
showed no difference (3.19 ± 0.62) in My1/De tumor bearing rats fed with cholesterol rich diet 
when beginning of the diet was equal to the time of tumor transplantation. Tumor bearing left 
kidney significantly increased (6.73 ± 0.69) in My1/De tumor bearing rats fed with cholesterol 
rich diet when beginning of the diet was two weeks earlier to the time of tumor transplanta-
tion. Weight of the right kidney did not differ (p = 0.1) using standard or cholesterol rich diet.
CONCLUSION: We have created a dyslipidemic tumor bearing rat model which model can 
be used for test of huge number of chemo preventive molecule quickly and efficiently in 
preclinical condition.
Nuclear Medicine Review 2017, Vol. 20, No. 2
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CLINICAL RELEVANCE OF TC-99m HDP SPECT/CT IN THE DIAGNOSIS  
OF SPONDYLOARTHROPATHIES
Annamária Bakos1, Zsuzsanna Besenyi1, Szabolcs Urbán1, Rita Hemelein2,  
László Kovács2, László Pávics1
1Department of Nuclear Medicine, University of Szeged 
2Department of Rheumatology, University of Szeged
INTRODUCTION: Spondyloarthropathies (SpA) belong to the group of inflammatory arthri-
tis which comprises the ankylosing spondylitis, reactive arthritis, psoriatic arthritis/spondylitis, 
and arthritis/spondylitis associated with inflammatory bowel diseases. The early diagnosis is ex-
tremely important for starting appropriate therapy in time. Our aim is to examine the clinical 
significance of 99mTc-HDP SPECT/CT in diagnosis of early and chronic axial SpA.
METHODS: Eight patients (5 females, 3 males, mean age: 42.7 years) were involved into 
the study from 2016 July. The patients were selected from the Department of Rheumatology 
according to the clinical features. Firstly, we performed examination of the sacroiliac joint with 
MRI in the following sequences: T1- weighted STIR for the bone marrow oedema (BME) and 
T2-weighted sequence for the fat metaplasia (FM). The HDP SPECT/CT was used within one 
week to examine the sacroiliac joint and spine. Thereafter, the MRI images were fused with 
SPECT/CT images (Mediso, Interview Fusion). On the MRI images the BME (active lesion) and 
FM (chronic lesion), on the CT scans the sclerotic lesions (Scl, chronic lesion) were drawn 
manually as volume of interest (VOI). Uninvolved cortical areas were drawn on the different 
modality slices as reference region (ref). Then, we determined the isotope (99mTc-labelled HDP) 
uptake of the different lesions and areas (mean counts/VOI): VOIBME/VOIref, VOIFM/VOIref, 
VOIScl/VOIref.
RESULTS: Two active sacroileitis and two chronic sacroileitis without active lesions were 
diagnosed. On the other 4 patient’s sacroiliac joints images (MRI, scintigraphy, CT scans) there 
were not any pathological lesions. Sixteen lesions of 8 patients were localised on the fused 
MRI-SPECT/CT images: 3 BME, 7 FM and 6 Scl lesions. The isotope uptake of BME was the 
highest (VOIBME/VOIref: 2.33). The radiopharmacon uptake of sclerotic lesions was moderate 
(VOIScl/VOIref: 1.56). The isotope uptake of FM lesions was not different from the HDP uptake 
of reference regions (VOIFM/VOIref: 0.97).
CONCLUSION: MRI is established modality in diagnosis of axial SpA. According to the 
initial results, the different MRI lesions have different isotope uptake, which suggests, that the 
HDP-SPECT/CT can distinguish the early and chronic stage of axial SpA. 
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PLACE AND ROLE OF SPECT-CT IN BONESCAN PRACTICE
J. Gombos, E. Kócsák, O. Sántha, Zs. Patkó 
Nuclear Diagnostic and Therapeutic Department, Borsod-Abaúj-Zemplén County Central 
Hospital and University Educational Hospital
INTRODUCTION: The use of SPECT-CT hybrid imaging modality in bone scintigraphy 
is nowadays routine. The aim of our review is to determine the location and role of this imaging 
procedure in the bone scintigraphy test, and to investigate the effect of the nuclear medicine 
hybrid test modality on SPECT-CT for the further load of imaging partners and patients.
METHODS: Our routine use of SPECT-CT equipment began in June 2013. From the nearly 
70000 bone scintigraphy studies performed since 1993, the time interval between 2013 and 
2016 was analyzed (18589 patients). We investigated the professional distribution of the 
initial diagnoses of patients referred to bone scintigraphy during this period, the proportion 
of SPECT-CT studies compared to all bone scintigraphy studies. We have determined the 
routine decision-making test process protocol we propose to analyze its justification steps. 
By analyzing the material of the year 2013, we have determined how the application of the 
SPECT-CT method affects our suggestion in the Nuclear Diagnostic Review for the co-imaging 
modalities and the patient’s further burden.
RESULTS: As expected, we received an extremely high oncology diagnosis (64%). By deve- 
loping a test protocol for bone scintigraphy, a routinely applicable decision-making element 
is available for everyday practice. In this process, the role of SPECT-CT is especially promi-
nent in differential diagnosis. The use of SPECT-CT (12% of all bone scintigraphy) resulted 
in a significant increase in the final diagnosis of the patient, reducing by more than 50% the 
co-imaging modalities and the additional adverse load of the patient, the cost of care, shorten-
ing the pathways of the patient.
CONCLUSIONS: Based on our results, the increase in the number of SPECT-CTs in the pro-
tocol is desirable to increase the differential diagnostic accuracy of benign-malignant bone 
lesions to further reduce the number of additional imaging procedures and the patient’s burden.
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IN VIVO IMAGING OF ISCHEMIA-REPERFUSION USING PET RADIOTRACERS
Gergely Farkasinszky1, Noémi Dénes1, György Trencsényi1, 2, Judit Szabó Péliné1, 
Tamás Nagy1, Adrienn Kis1, Alexandra Kocsel1, Gábor Mezö4, Ervin Berényi1, 
István Kertész1, János Hunyadi3
1Division of Nuclear Medicine, Department of Medical Imaging, University of Debrecen 
2Scanomed LTD, Debrecen 
3Department of Dermatology, University of Debrecen 
4Research Group of Peptide Chemistry, MTA-ELTE, Budapest
INTRODUCTION: Angiogenesis is the process of new blood vessel formation. One can be 
observed physiologically in wound healing and embryogenesis but it has discovered in several 
human pathological disorders such as tumors, coronary artery disease or retinopathia diabetica. 
The asparagine-glycine-arginine (NGR) peptide sequence known as a possible biomarker of 
angiogenesis. Previous studies have shown that the NGR peptides are specifically bind to 
APN/CD13 molecules expressed by tumors. Ga-68 labeled NGR peptides allowed the preclinical 
PET conducted non-invasive detection of neo-angiogenic processes.
METHODS: The peptides were synthetized by solid phase peptide synthesis. The NGR 
derivate was conjugated with NOTA macrocyclic chelator. The complete ligand was purified 
by RP-HPLC and then was lyophilized. The product was characterized by MS. The labeling 
optimization experiments were accomplished with Ga-68 at room temperature and at 95 °C.
Left eye of rats (Fischer-344) (n = 5) were ligated surgically using a cannula guided loop. 
Ischemia can be induced by tightening the noose (90 min.) furthermore it can be terminated 
by loosening it. The upper mentioned surgical procedure suitable to develop lesions that occur 
during reperfusion. One day after ischemia-reperfusion (I/R) induction labeled radioligand 
(15 MBq in 150 μl saline) was injected intravenously (lateral tail vein) to surgical and non-surgical 
control (n = 2) groups. After the appropriate incubation time (90 min) the radiopharmaceuti-
cal distribution was determined in vivo using PET (MiniPET-II small animal PET scanner) and 
CT (Micro-CT).
RESULTS: NGR derivate conjugation with NOTA chelator was prepared successfully. 
68Ga-NOTA-c(NGR) was produced with high specific activity (5.13–5.92 GBq/µmol) and with 
excellent radiochemical purity (95% <), at all cases. The quantitate labeling range was deter-
mined. It was over 10 μmol/dm3. The octanol-PBS partition coefficient (LogP) of the radiolabeled 
compound was successfully defined. 
In the left bulbus of the surgical group significantly (p ≤ 0.05) higher tracer uptake was observed 
(SUV mean) compared to the control (internal control) and non-surgical control group. Western 
blot analysis confirmed the presence of neo-angiogenic markers (APN/CD13).
CONCLUSION: The above outlined application ideal for study in vivo I/R mediated receptor 
expression in rat eye model. Thus, creates an opportunity to develop modern diagnostic 
methods in various pathological processes.
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FDG UPTAKE CHARACTERISTICS OF MALIGNANT PULMONARY TUMORS 
EXPERIENCES OF KAPOSVÁR
Zoltán Tóth1, 7, Gábor Lukács2, 3, 7, Miklós Emri1, 5, Zsolt Cselik2, 4, Éva Somogyiné 
Ezer3, Márta Vallyon3, Ágnes Ruzsa3, Szabina Nagy6, József Mendly1, 2,  
Gábor Bajzik1, 2, Imre Repa2, Árpád Kovács2, 7 
1PET Medicopus Nonprofit Ltd., Health Center, University of Kaposvár 
2Department of Diagnostic Imaging and Radiation Oncology, Health Center, University of 
Kaposvár  
3Department of Oncology, Somogy County Moritz Kaposi Teaching Hospital  
4Radiation Oncology, Regional Oncology Centre Veszprém  
5Department of Medical Imaging, University of Debrecen  
6Medical Laboratorial Diagnostic Imaging Analysis BSC, Department of Medical Imaging 
Kaposvár Campus, University of Pécs Faculty of Health Sciences  
7Doctoral School, University of Pécs Faculty of Health Sciences 
INTRODUCTION: Malignant lung cancer is one of first established and nowadays still the most 
common FDG PET/CT indication. We evaluated the FDG uptake intensity of different histo-
logical type pulmonary cancers and analysed the semiquantitative SUV based discrimination 
opportunities using PET/CT imaging data of PET Medicopus Nonprofit Ltd.
METHODS: PET/CT examinations of 215 patients (149 men, 66 women) acquired in our 
institute between September 2014 and 2016 were retrospective evaluated. All patients under-
went stage assessment oncological whole body scan, due to verified malignant lung cancer 
(104 adenocarcinoma, 96 squamous cell carcinoma, 7 large cell carcinoma, 3 adenosqua-
mous carcinoma, 2 carcinoid tumor, and 1 lepidic carcinoma, 1 small cell lung cancer and 
1 angiosarcoma) larger than 2 cm in diameter. Lean body mass normalized SUVmax values of 
corresponding pulmonary lesions were calculated using spheric VOI measurement provided 
by Syngo.via application. The semiquantitative tracer uptake values of pulmonary foci were 
correlated to available histological data. 
RESULTS: The pulmonary lesions showed variable FDG uptake, tumors with high intensity 
tracer accumulation and only faint uptake were also found [SUV(lbm)max ranged from 1.2 to 
29.7]. The lowest uptake was detected for an adenocarcinoma lesion while a squamous cell 
tumor visualized with the most intensive FDG accumulation. The statistical analysis of the two 
subgroups containing sufficient number of lesions revealed significantly higher intensity FDG 
accumulation for squamous cell cancers than for adenocarcinomas (t-test, p < 0.00005), 
however a considerable overlap between the two groups were also found. 
CONCLUSION: In concordance with the international literature data significant difference 
was found in the FDG accumulation intensity of squamous cell lung cancers and adenocarci-
noma types using our own lung cancer patient population, however due to the considerable 
overlap, semiquantitative SUV(lbm)max parameter was unable to provide individual histologi-
cal prediction.
